US20020039775A1

US20020039775A1 - Sulfotransferase sequence variants

Info

Publication number: US20020039775A1
Application number: US09/829,545
Authority: US
Inventors: Richard Weinshilboum; Rebecca Raftogianis; Thomas Wood; Diane Otterness
Original assignee: Mayo Foundation for Medical Education and Research
Current assignee: Mayo Foundation for Medical Education and Research
Priority date: 1998-10-07
Filing date: 2001-04-10
Publication date: 2002-04-04
Also published as: AU6289199A; US6265561B1; WO2000020605A1; WO2000020605A9; US20040235098A1

Abstract

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described. Methods for determining a risk estimate for hormone dependent disease and methods for determining sulfonator status also are described.

Description

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

[0001] Funding for the work described herein was provided by the federal government, which has certain rights in the invention.

TECHNICAL FIELD

The invention relates to sulfotransferase nucleic acid sequence variants.

BACKGROUND OF THE INVENTION

Pharmacogenetics is the study of the role of inheritance in variation of drug response, a variation that often results from individual differences in drug metabolism. Sulfation is an important pathway in the metabolism of many neurotransmitters, hormones, drugs and other xenobiotics. Sulfate conjugation is catalyzed by members of a gene superfamily of cytosolic sulfotransferase enzymes. It was recently agreed that “SULT” will be used as an abbreviation for these enzymes. These enzymes also are known as “PSTs” in the literature. Included among the nine cytosolic SULTs presently known to be expressed in human tissues are three phenol SULTs, SULT1A1, 1A2 and 1A3, which catalyze the sulfate conjugation of many phenolic drugs and other xenobiotics.

Biochemical studies of human phenol SULTs led to the identification of two isoforms that were defined on the basis of substrate specificities, inhibitor sensitivities and thermal stabilities. A thermostable (TS), or phenol-preferring form, and a thermolabile (TL), or monoamine-preferring form, were identified. “TS PST” preferentially catalyzed the sulfation at micromolar concentrations of small planar phenols such as 4-nitrophenol and was sensitive to inhibition by 2,6-dichloro-4-nitrophenol (DCNP). “TL PST” preferentially catalyzed the sulfation of micromolar concentration of phenolic monoamines such as dopamine and was relatively insensitive to DCNP inhibition. Weinshilboum, R. M. Fed. Proc., 45:2223 (1986). Both of these biochemically-defined activities were expressed in a variety of human tissues including liver, brain, jejunum and blood platelets. Human platelet TS PST displayed wide individual variations, not only in level of activity, but also in thermal stability. Segregation analysis of data from family studies of human platelet TS PST showed that levels of this activity as well as individual variations in its thermal stability were controlled by genetic variation. Price, P. A. et al., Genetics, 122:905-914 (1989).

Molecular genetic experiments indicated that there are three “PST genes” in the human genome, two of which, SULT1A1 (STP1) and SULT1A2 (STP2), encode proteins with TS PST-like activity, SULT1A1 (TS PST1) and SULT1A2 (TS PST2), respectively. The remaining gene, SULT1A3 (STM), encodes a protein with TL PST-like activity, SULT1A3 (TL PST). DNA sequences and structures of the genes for these enzymes are highly homologous, and all three map to a phenol SULT gene complex on the short arm of human chromosome 16. Weinshilboum, R. et al., FASEB J., 11(1):3-14 (1997).

SUMMARY OF THE INVENTION

The invention is based on the discovery of several common SULT1A1 and SULT1A2 alleles encoding enzymes that differ functionally and are associated with individual differences in phenol SULT properties in platelets and liver. In addition, the invention is based on the discovery of SULT1A3 sequence variants. These discoveries permit use of SULT genomic and biochemical pharmacogenetic data to better understand the possible contribution of inheritance to individual differences in the sulfate conjugation of drugs and other xenobiotics in humans. Thus, the identification of SULT allozymes and alleles allows sulfonator status of a subject to be assessed. The information and insight obtained thereby allows tailoring of particular treatment regimens in the subject. In addition, risk estimates for hormone dependent diseases can be determined.

The invention features an isolated nucleic acid molecule including a SULT1A3 nucleic acid sequence. The sulfotransferase nucleic acid sequence includes a nucleotide sequence variant and nucleotides flanking the sequence variant. A nucleic acid construct that includes such sulfotransferase nucleic acid sequences is also described. The SULT1A3 sulfotransferase nucleic acid sequence can encode a sulfotransferase polypeptide including an amino acid sequence variant. SULT1A3 nucleotide sequence variants can be within an intron. For example, introns 4 and 6 each can include an adenine at nucleotide 69. Intron 7 can include a thymine at nucleotide 113. SULT1A3 nucleotide sequence variants can include insertion of nucleotides within intron sequences. The nucleotide sequence 5′-CAGT-3′ can be inserted, for example, within intron 3. A SULT1A3 nucleotide sequence variant also can include a guanine at nucleotide 105 of the coding sequence.

The invention also features SULT1A1 and SULT1A2 nucleotide sequence variants. The SULT1A1 nucleotide sequence variants can include, for example, a cytosine at nucleotide 138 of intron 1A or a thymine at nucleotide 34 of intron 5. A SULT1A1 variant also can include, for example, an adenine at nucleotide 57, 110, or 645 of the SULT1A1 coding sequence. The SULT1A1 nucleic acid sequence can encode a sulfotransferase polypeptide having, for example, a glutamine at amino acid 37. SULT1A2 nucleotide sequence variants can include a thymine at nucleotide 78 of intron 5 or a thymine at nucleotide 9 of intron 7. The coding sequence of SULT1A2 can include a thymine of nucleotide 550. The SULT1A2 nucleic acid sequence can encode, for example a cysteine at amino acid 184.

In another aspect, the invention features a method for determining a risk estimate of a hormone disease in a patient. The method includes detecting the presence or absence of a sulfotransferase nucleotide sequence variant in a patient, and determining the risk estimate based, at least in part, on presence or absence of the variant in the patient. The hormone dependent disease can be, for example, breast cancer, prostate cancer or ovarian cancer.

The invention also features a method for determining sulfonator status in a subject. The method includes detecting the presence or absence of a sulfotransferase allozyme or nucleotide sequence variant in a subject, and determining the sulfonator status based, at least in part, on said determination.

An antibody having specific binding affinity for a sulfotransferase polypeptide is also described.

The invention also features isolated nucleic acid molecules that include a sulfotransferase nucleic acid sequence that encode a sulfotransferase allozyme. The allozyme can be selected from the group consisting of SULT1A1*4, SULT1A2*4, SULT1A2*5, and SULT1A2*6. Sulfotransferase nucleic acid sequences that include sulfotransferase alleles selected from the group consisting of SULT1A1*1, SULT1A1*2, SULT1A1*3A, SULT1A1*3B and SULT1A1*4 also are featured. In particular, the SULT1A1*1 allele can be SULT1A1*1A to SULT1A1*1K. The SULT1A2 allele can be SULT1A2*1A-1D, SULT1A2*2A-2C, SULT1A2*3A-3C or SULT1A2*4-*6.

The invention also relates to an article of manufacture that includes a substrate and an array of different sulfotransferase nucleic acid molecules immobilized on the substrate. Each of the different sulfotransferase nucleic acid molecules includes a different sulfotransferase nucleotide sequence variant and nucleotides flanking the sequence variant. The array of different sulfotransferase nucleic acid molecules can include at least two nucleotide sequence variants of SULT1A1, SULT1A2, or SULT1A3.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 represents human platelet TS PST phenotypes. [0016]
FIG. 1A is a scattergram that depicts the relationship between TS PST enzymatic activity and thermal stability in 905 human platelet samples. [0017]
FIG. 1B is a scattergram that correlates human platelet SULT1A1 genotype with TS PST phenotype. [0018]
FIG. 2 is a representation of human SULT1A1, SULT1A2, and SULT1A3 gene structures and the PCR strategy used to amplify the open reading frame (ORF) of each gene in three segments. Black rectangles represent exons that encode cDNA ORF sequence, while open rectangles represent exon or portions of exons that encode cDNA untranslated region (UTR) sequence. Roman numerals are exon numbers, and arabic numerals are exon lengths in bp. Gene lengths in kb from initial to final exons are also indicated. Forward and reverse arrows indicate the placement within introns of the PCR primers used to amplify, in three separate reactions, the ORFs of SULT1A1 and SULT1A2. [0019]
FIG. 3 is a scattergram that depicts the relationship between TS PST enzymatic activity and thermal stability in 61 human liver biopsy samples. [0020]
FIGS. 4A and 4B are scattergrams that depict the correlation of SULT1A1 and SULT1A2 genotypes with human liver TS PST phenotype. TS PST phenotypes in the human liver samples depicted as in FIG. 3 are shown with (A) common SULT1A1 allozymes or (B) common SULT1A2 allozymes superimposed. In (B) three samples are not shown because they contain SULT1A2 allozymes that were observed only once in this population sample. [0021]
FIG. 5 is the gene sequence of SULT1A1 (SEQ ID NO:29). [0022]
FIG. 6 is the gene sequence of SULT1A2 (SEQ ID NO:31). [0023]
FIG. 7 is the gene sequence of SULT1A3 (SEQ ID NO:33).[0024]

DETAILED DESCRIPTION

The invention features an isolated nucleic acid molecule that includes a sulfotransferase nucleic acid sequence. The sulfotransferase nucleic acid sequence includes a nucleotide sequence variant and nucleotides flanking the sequence variant. As used herein, “isolated nucleic acid” refers to a sequence corresponding to part or all of the sulfotransferase gene, but free of sequences that normally flank one or both sides of the sulfotransferase gene in a mammalian genome. The term “sulfotransferase nucleic acid sequence” refers to a nucleotide sequence of at least about 14 nucleotides in length. For example, the sequence can be about 14 to 20, 20-50, 50-100 or greater than 100 nucleotides in length. Sulfotransferase nucleic acid sequences can be in sense or antisense orientation. Suitable sulfotransferase nucleic acid sequences include SULT1A1, SULT1A2 and SULT1A3 nucleic acid sequences. As used herein, “nucleotide sequence variant” refers to any alteration in the wild-type gene sequence, and includes variations that occur in coding and non-coding regions, including exons, introns, promoters and untranslated regions. [0025]
In some instances, the nucleotide sequence variant results in a sulfotransferase polypeptide having an altered amino acid sequence. The term “polypeptide” refers to a chain of at least four amino acid residues. Corresponding sulfotransferase polypeptides, irrespective of length, that differ in amino acid sequence are herein referred to as allozymes. For example, a sulfotransferase nucleic acid sequence can be a SULT1A1 nucleic acid sequence and include an adenine at nucleotide 110. This nucleotide sequence variant encodes a sulfotransferase polypeptide having a glutamine at amino acid residue 37. This polypeptide would be considered an allozyme with respect to a corresponding sulfotransferase polypeptide having an arginine at amino acid residue 37. In addition, the nucleotide variant can include an adenine at nucleotide 638 or a guanine at nucleotide 667, and encode a sulfotransferase polypeptide having a histidine at amino acid residue 213 or a valine at amino acid residue 223, respectively. [0026]
As described herein, there are at least four SULT1A1 allozymes. SULT1A1*1 is the most common and contains an arginine at residues 37 and 213, and a methionine at residue 223. SULT1A1*2 contains an arginine at residue 37, a histidine at residue 213 and a methionine at residue 223. SULT1A1*3 contains an arginine at residues 37 and 213, and a valine at residue 223. SULT1A*4 is the least common, and contains a glutamine at residue 37, an arginine at residue 213, and a methionine at residue 223. [0027]
The sulfotransferase nucleic acid sequence also can encode SULT1A2 polypeptide variants. Non-limiting examples of SULT1A2 polypeptide variants include an isoleucine at [0028] amino acid residue 7, a leucine at amino acid residue 19, a cysteine at amino acid residue 184, or a threonine at amino acid 235. These polypeptide variants are encoded by nucleotide sequence variants having a cytosine at nucleotide 20, a thymine at nucleotide 56, a thymine at nucleotide 50 and a cytosine at nucleotide 704.
There are at least six different SULT1A2 allozymes that differ at [0029] residues 7, 19, 184 and 235. For example, SULT1A2*1 contains an isoleucine, a proline, an arginine and an asparagine at residues 7, 19, 184 and 235, respectively, and represents the most common allozyme. SULT1A2*2 differs from SULT1A2*1 in that it contains a threonine at residues 7 and 235. SULT1A2*3 differs from SULT1A2*1 in that it contains a leucine at residue 19. SULT1A2*4 differs from SULT1A2*2 in that it contains a cysteine at residue 184. SULT1A2*5 differs from SULT1A2*1 in that it contains a threonine at residue 7. SULT1A2*6 differs from SULT1A2*1 in that it contains an isoleucine at residue 7.
As described herein, SULT1A1*2 and SULT1A2*2 are associated with decreased TS PST thermal stability in the human liver, but the biochemical and physical properties of recombinant SULT allozymes indicated that the “TS PST phenotype” in the liver is most likely due to expression of SULT1A1. For example, based both on its apparent K[0030] _mvalue for 4-nitrophenol and its T₅₀value, SULT1A1*2 was not consistently associated with low levels of TS PST activity in the liver, but was uniformly associated with decreased levels of platelet TS PST activity and thermal stability. It appears that SULT1A1*2 is associated with lower levels of TS PST activity in tissue from subjects with benign rather than neoplastic disease.
Certain sulfotransferase nucleotide variants do not alter the amino acid sequence. Such variants, however, could alter regulation of transcription as well as mRNA stability. SULT1A1 variants can occur in intron sequences, for example, within [0031] intron 1A and introns 5-7 (i.e., intron 5 is immediately after exon 5 in FIG. 5). In particular, the nucleotide sequence variant can include a cytosine at nucleotide 138 of intron 1A, or a thymine at nucleotide 34 or an adenine at nucleotide 35 of intron 5. Intron 6 sequence variants can include a guanine at nucleotide 11, a cytosine at nucleotide 17, an adenine at nucleotide 35, a guanine at nucleotide 45, a guanine at nucleotide 64, a cytosine at nucleotide 488, and an adenine at nucleotide 509. Intron 7 variants can include a thymine at nucleotide 17, a cytosine at nucleotide 69 and a guanine at nucleotide 120. SULT1A1 nucleotide sequence variants that do not change the amino acid sequence also can be within an exon or in the 3′ untranslated region. For example, the coding sequence can contain an adenine at nucleotide 57, a cytosine at nucleotide 153, a guanine at nucleotide 162, a cytosine at nucleotide 600, or an adenine at nucleotide 645. The 3′ untranslated region can contain a guanine at nucleotide 902 or a thymine at nucleotide 973.
Similarly, certain SULT1A2 and SULT1A3 variants do not alter the amino acid sequence. Such SULT1A2 nucleotide sequence variants can be within an intron sequence, a coding sequence or within the 3′ untranslated region. In particular, the nucleotide variant can be within [0032] intron 2, 5 or 7. For example, intron 2 can contain a cytosine at nucleotide 34. Intron 5 can include a thymine at nucleotide 78, and intron 7 can include a thymine at nucleotide 9. In addition, a cytosine can be at nucleotide 24 or a thymine at nucleotide 895 in SULT1A2 coding sequence. A guanine can be at nucleotide 902 in the 3′ untranslated region. SULT1A3 nucleotide sequences variant can include a guanine at nucleotide 105 of the coding region (within exon 3). In addition, intron 3 of SULT1A3 can include an insertion of nucleotides. For example, the four nucleotides 5′-CAGT-3′ can be inserted between nucleotides 83 and 84 of intron 3. Introns 4, 6, and 7 also can contain sequence variants. For example, nucleotide 69 of introns 4 and 6 can contain an adenine. Nucleotide 113 of intron 7 can contain a thymine.
Sulfotransferase allozymes as described above are encoded by a series of sulfotransferase alleles. These alleles represent nucleic acid sequences containing sequence variants, typically multiple sequence variants, within intron, exon and 3′ untranslated sequences. Representative examples of single nucleotide variants are described above. Table 3 sets out a series of 13 SULT1A1 alleles (SULT1A1*1A to SULT1A1*1K) that encode SULT1A1*1. SULT1A1*1A to SULT1A1*1K range in frequency from about 0.7% to about 33%, as estimated from random blood donors and hepatic biopsy samples. Two alleles, SULT1A1*3A and SULT1A1*3B each encode SULT1A1*3, and represent about 0.3% to about 1.6% of all SULT1A1 alleles. SULT1A1*2 and SULT1A1*4 are encoded by single alleles, SULT1A1*2 and SULT1A1*4, respectively. SULT1A1*2 represents about 31% of the alleles, whereas SULT1A1*4 accounts for only about 0.3% of the alleles. [0033]
Numerous SULT1A2 alleles also exist (Table 2A). For example, SULT1A2*1 is encoded by four alleles (SULT1A2*1A to SULT1A2*1D) that range in frequency from 0.8% to about 47%. SULT1A2*2 and SULT1A2*3 are each encoded by three alleles (*2A-*2C and *3A-*3C). These alleles range in frequency from 0.8% up to about 26%. Single alleles encode SULT1A2*4, SULT1A2*5, and SULT1A2*6, with each representing about 0.8% of the SULT1A2 alleles. As described herein, SULT1A2 alleles are in linkage disequilibrium with the alleles for SULT1A1. [0034]
The relatively large number of alleles and allozymes for SULT1A1 and SULT1A2, with three common allozymes for each gene, indicates the potential complexity of SULT pharmacogenetics. Such complexity emphasizes the need for determining single nucleotide variants, as well as complete haplotypes of patients. For example, an article of manufacture that includes a substrate and an array of different sulfotransferase nucleic acid molecules immobilized on the substrate allows complete haplotypes of patients to be assessed. Each of the different sulfotransferase nucleic acid molecules includes a different sulfotransferase nucleotide sequence variant and nucleotides flanking the sequence variant. The array of different sulfotransferase nucleic-acid molecules can include at least two nucleotide sequence variants of SULT1A1, SULT1A2, or SULT1A3, or can include all of the nucleotide sequence variants known for each gene. [0035]
Suitable substrates for the article of manufacture provide a base for the immobilization of nucleic acid molecules into discrete units. For example, the substrate can be a chip or a membrane. The term “unit” refers to a plurality of nucleic acid molecules containing the same nucleotide sequence variant. Immobilized nucleic acid molecules are typically about 20 nucleotides in length, but can vary from about 14 nucleotides to about 100 nucleotides in length. In practice, a sample of DNA or RNA from a subject can be amplified, hybridized to the article of manufacture, and then hybridization detected. Typically, the amplified product is labeled to facilitate hybridization detection. See, for example, Hacia, J. G. et al., [0036] Nature Genetics, 14:441-447 (1996); and U.S. Pat. Nos. 5,770,722 and 5,733,729.
As a result of the present invention, it is now possible to determine sulfonator status of a subject. As used herein “sulfonator status” refers to the ability of a subject to transfer a sulfate group to a substrate. A variety of drugs (e.g., acetaminophen), hormones (e.g., estrogen) and neurotransmitters <e.g., dopamine and other phenolic monoamines) are substrates for these enzymes. Generally, sulfonation is considered a detoxification mechanism, as reaction products are more readily excreted. Certain substrates, however, become more reactive upon sulfonation. For example, the N-hydroxy metabolite of 2-acetylaminoflourene is converted to a N-O-sulfate ester, which is reactive with biological macromolecules. Thus, a determination of the presence or absence of nucleotide sequence variants or allozymes facilitates the prediction of therapeutic efficacy and toxicity of drugs on an individual basis, as well as the ability to biotransform certain hormones and neurotransmitters. In addition, the ability to sulfonate hormones may play a role in cancer. [0037]
The presence or absence of sulfotransferase variants allows the determination of a risk estimate for the development of a hormone dependent disease. As used herein, “hormone dependent disease” refers to a disease in which a hormone plays a role in the pathophysiology of the disease. Non-limiting examples of hormone dependent diseases include breast cancer, ovarian cancer, and prostate cancer. Risk estimate indicates the relative risk a subject has for developing a hormone dependent disease. For example, a risk estimate for development of breast cancer can be determined based on the presence or absence of sulfotransferase variants. A subject containing, for example, the SULT1A1*2, of sulfotransferase variant may have a greater likelihood of having breast cancer. Additional risk factors include, for example, family history of breast cancer and other genetic factors such as mutations within the BRCA1 and BRCA2 genes. [0038]
Sulfotransferase nucleotide sequence variants can be assessed, for example, by sequencing exons and introns of the sulfotransferase genes, by performing allele-specific hybridization, allele-specific restriction digests, mutation specific polymerase chain reactions (MSPCR), or by single-stranded conformational polymorphism (SSCP) detection. Polymerase chain reaction (PCR) refers to a procedure or technique in which target nucleic acids are amplified. Generally, sequence information from the ends of the region of interest or beyond is employed to design oligonucleotide primers that are identical or similar in sequence to opposite strands of the template to be amplified. PCR can be used to amplify specific sequences from DNA as well as RNA, including sequences from total genomic DNA or total cellular RNA. Primers are typically 14 to 40 nucleotides in length, but can range from 10 nucleotides to hundreds of nucleotides in length. PCR is described, for example in [0039] PCR Primer: A Laboratory Manual, Ed. by Dieffenbach, C. and Dveksler, G., Cold Spring Harbor Laboratory Press, 1995. Nucleic acids also can be amplified by ligase chain reaction, strand displacement amplification, self-sustained sequence replication or nucleic acid sequence-based amplification. See, for example, Lewis, R. Genetic Engineering News, 12(9):1 (1992); Guatelli et al., Proc. Natl. Acad. Sci. USA, 87:1874-1878 (1990); and Weiss, R., Science, 254:1292 (1991).
Genomic DNA is generally used in the analysis of sulfotransferase nucleotide sequence variants. Genomic DNA is typically extracted from peripheral blood samples, but can be extracted from such tissues as mucosal scrapings of the lining of the mouth or from renal or hepatic tissue. Routine methods can be used to extract genomic DNA from a blood or tissue sample, including, for example, phenol extraction. Alternatively, genomic DNA can be extracted with kits such as the QIAamp® Tissue Kit (Qiagen, Chatsworth, Calif.), Wizard® Genomic DNA purification kit (Promega, Madison, Wis.) and the A.S.A.P.™ Genomic DNA isolation kit (Boehringer Mannheim, Indianapolis, Ind.). [0040]
For example, exons and introns of the sulfotransferase gene can be amplified through PCR and then directly sequenced. This method can be varied, including using dye primer sequencing to increase the accuracy of detecting heterozygous samples. Alternatively, a nucleic acid molecule can be selectively hybridized to the PCR product to detect a gene variant. Hybridization conditions are selected such that the nucleic acid molecule can specifically bind the sequence of interest, e.g., the variant nucleic acid sequence. Such hybridizations typically are performed under high stringency as some sequence variants include only a single nucleotide difference. High stringency conditions can include the use of low ionic strength solutions and high temperatures for washing. For example, nucleic acid molecules can be hybridized at 42° C. in 2×SSC (0.3M NaCl/0.03 M sodium citrate/0.1% sodium dodecyl sulfate (SDS) and washed in 0.1×SSC (0.015M NaCl/0.0015 M sodium citrate), 0.1% SDS at 65° C. Hybridization conditions can be adjusted to account for unique features of the nucleic acid molecule, including length and sequence composition. [0041]
Allele-specific restriction digests can be performed in the following manner. For example, if a nucleotide sequence variant introduces a restriction site, restriction digest with the particular restriction enzyme can differentiate the alleles. For SULT1 variants that do not alter a common restriction site, primers can be designed that introduce a restriction site when the variant allele is present, or when the wild-type allele is present. For example, the SULT1A*2 allele does not have an altered restriction site. A KasI site can be introduced in all SULT1A1 alleles, except SULT1A*2, using a mutagenic primer (e.g., 5′CCA CGG TCT CCT CTG [0042] GCA GGG GG 3′, SEQ ID NO:1). A portion of SULT1A1 alleles can be amplified using the mutagenic primer and a primer having, for example, the nucleotide sequence of 5′ GTT GAG GAG TTG GCT CTG CAG GOT C 3′ (SEQ ID NO:2). A KasI digest of SULT1A1 alleles, other than SULT1A*2, yield restriction products of about 173 base pairs (bp) and about 25 bp. In contrast, the SULT1A*2 allele is not cleaved, and thus yields a restriction product of about 198 bp.
The SULT1A2*2 allele can be detected using a similar strategy. For example, an additional StyI site can be introduced in the SULT1A2*2 allele using the mutagenic primer 5′ CAC GTA CTC CAG TGG CGG [0043] GCC CTA G 3′ (SEQ ID NO:3). Upon amplification of a portion of the SULT1A2 alleles using the mutagenic primer and a primer having the nucleotide sequence of 5′ GGA ACC ACC ACA TTA GAA C 3′ (SEQ ID NO:4), a StyI digest yields restriction products of 89 bp, 119 bp and 25 bp for SULT1A2*2. The other SULT1A2 alleles described herein yield restriction products of 89 bp and 144 bp.
Certain variants, such as the insertion within [0044] intron 3 of the SULT1A3 gene discussed above, change the size of the DNA fragment encompassing the variant. The insertion of nucleotides can be assessed by amplifying the region encompassing the variant and determining the size of the amplified products in comparison with size standards. For example, the intron 3 region of the SULT1A3 gene can be amplified using a primer set from either side of the variant. One of the primers is typically labeled, for example, with a fluorescent moiety, to facilitate sizing. The amplified products can be electrophoresed through acrylamide gels using a set of size standards that are labeled with a fluorescent moiety that differs from the primer.
PCR conditions and primers can be developed that amplify a product only when the variant allele is present or only when the wild-type allele is present (MSPCR or allele-specific PCR). For example, patient DNA and a control can be amplified separately using either a wild-type primer or a primer specific for the variant allele. Each set of reactions is then examined for the presence of amplification products using standard methods to visualize the DNA. For example, the reactions can be electrophoresed through an agarose gel and DNA visualized by staining with ethidium bromide or other DNA intercalating dye. In DNA samples from heterozygous patients, reaction products would be detected in each reaction. Patient samples containing solely the wild-type allele would have amplification products only in the reaction using the wild-type primer. Similarly, patient samples containing solely the variant allele would have amplification products only in the reaction using the variant primer. [0045]
Mismatch cleavage methods also can be used to detect differing sequences by PCR amplification, followed by hybridization with the wild-type sequence and cleavage at points of mismatch. Chemical reagents, such as carbodiimide or hydroxylamine and osmium tetroxide can be used to modify mismatched nucleotides to facilitate cleavage. [0046]
Alternatively, sulfotransferase nucleotide sequence variants can be detected by antibodies that have specific binding affinity for variant sulfotransferase polypeptides. Variant sulfotransferase polypeptides can be produced in various ways, including recombinantly. The genomic nucleic acid sequences of SULT1A1, SULT1A2 and SULT1A3 have GenBank accession numbers of U52852, U34804 and U20499, respectively. Amino acid changes can be introduced by standard techniques including oligonucleotide-directed mutagenesis and site-directed mutagenesis through PCR. See, [0047] Short Protocols in Molecular Biology, Chapter 8, Green Publishing Associates and John Wiley & Sons, Edited by Ausubel, F. M et al., 1992.
A nucleic acid sequence encoding a sulfotransferase variant polypeptide can be ligated into an expression vector and used to transform a bacterial or eukaryotic host cell. In general, nucleic acid constructs include a regulatory sequence operably linked to a sulfotransferase nucleic acid sequence. Regulatory sequences do not typically encode a gene product, but instead affect the expression of the nucleic acid sequence. In bacterial systems, a strain of [0048] Escherichia coli such as BL-21 can be used. Suitable E. coli vectors include the pGEX series of vectors that produce fusion proteins with glutathione S-transferase (GST). Transformed E. coli are typically grown exponentially, then stimulated with isopropylthiogalactopyranoside (IPTG) prior to harvesting. In general, such fusion proteins are soluble and can be purified easily from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
In eukaryotic host cells, a number of viral-based expression systems can be utilized to express sulfotransferase variant polypeptides. A nucleic acid encoding a sulfotransferase variant polypeptide can be cloned into, for example, a baculoviral vector and then used to transfect insect cells. Alternatively, the nucleic acid encoding a sulfotransferase variant can be introduced into a SV40, retroviral or vaccinia based viral vector and used to infect host cells. [0049]
Mammalian cell lines that stably express sulfotransferase variant polypeptides can be produced by using expression vectors with the appropriate control elements and a selectable marker. For example, the eukaryotic expression vector pCR3.1 (Invitrogen, San Diego, Calif.) is suitable for expression of sulfotransferase variant polypeptides in, for example, COS cells. Following introduction of the expression vector by electroporation, DEAE dextran, or other suitable method, stable cell lines are selected. Alternatively, amplified sequences can be ligated into a mammalian expression vector such as pcDNA3 (Invitrogen, San Diego, Calif.) and then transcribed and translated in vitro using wheat germ extract or rabbit reticulocyte lysate. [0050]
Sulfotransferase variant polypeptides can be purified by known chromatographic methods including DEAE ion exchange, gel filtration and hydroxylapatite chromatography. Van Loon, J. A. and R. M. Weinshilboum, [0051] Drug Metab. Dispos., 18:632-638 (1990); Van Loon, J. A. et al., Biochem. Pharmacol., 44:775-785 (1992).
Various host animals can be immunized by injection of a sulfotransferase variant polypeptide. Host animals include rabbits, chickens, mice, guinea pigs and rats. Various adjuvants that can be used to increase the immunological response depend on the host species and include Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin and dinitrophenol. Polyclonal antibodies are heterogenous populations of antibody molecules that are contained in the sera of the immunized animals. Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be prepared using a sulfotransferase variant polypeptide and standard hybridoma technology. In particular, monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described by Kohler, G. et al., [0052] Nature, 256:495 (1975), the human B-cell hybridoma technique (Kosbor et al., Immunology Today, 4:72 (1983); Cole et al., Proc. Natl. Acad. Sci USA, 80:2026 (1983)), and the EBV-hybridoma technique (Cole et al., “Monoclonal Antibodies and Cancer Therapy”, Alan R. Liss, Inc., pp. 77-96 (1983). Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the monoclonal antibodies of the invention can be cultivated in vitro and in vivo.
Antibody fragments that have specific binding affinity for a sulfotransferase variant polypeptide can be generated by known techniques. For example, such fragments include but are not limited to F(ab′)[0053] ₂fragments that can be produced by pepsin digestion of the antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab′)₂fragments. Alternatively, Fab expression libraries can be constructed. See, for example, Huse et al., Science, 246:1275 (1989). Once produced, antibodies or fragments thereof are tested for recognition of sulfotransferase variant polypeptides by standard immunoassay methods including ELISA techniques, radioimmunoassays and Western blotting. See, Short Protocols in Molecular Biology, Chapter 11, Green Publishing Associates and John Wiley & Sons, Edited by Ausubel, F. M et al., 1992.
The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. [0054]

EXAMPLES

1.0 Methods and Materials [0055]
1.1 Tissue Samples [0056]
Human hepatic “surgical waste” tissue was obtained from 61 patients undergoing clinically-indicated hepatectomies or open hepatic biopsies and was stored at −80° C. These frozen hepatic tissue samples were homogenized in 5 mM potassium phosphate buffer, pH 6.5, and centrifuged at 100,000×g for 1 hr to obtain high-speed supernatant (HSS) cytosolic preparations. Campbell, N. R. C. et al., [0057] Biochem. Pharmacol., 36:1435-1446 (1987). Platelet samples were obtained from blood samples from 905 members of 134 randomly selected families at the Mayo Clinic in Rochester, Minn. All tissue samples were obtained under guidelines approved by the Mayo Clinic Institutional Review Board.
1.2 PST Enzyme Activity, Thermal Stability and Inhibitor Sensitivity [0058]
TS PST enzyme activity was measured with an assay that involves the sulfate conjugation of substrate, in this case 4-nitrophenol, in the presence of [[0059] ³⁵S]-3′-phosphoadenosine-5′-phosphosulfate (PAPS), the sulfate donor for the reaction. See, Campbell, N. R. C. et al., Biochem. Pharmacol., 36:1435-1446 (1987). Blanks were samples that did not contain sulfate acceptor substrate. Unless otherwise stated, concentrations of 4-nitrophenol and PAPS were 4 μM and 0.4 μM, respectively. Substrate kinetic experiments were conducted in the presence of a series of concentrations of 4-nitrophenol and PAPS to make it possible to calculate apparent K_mvalues. Enzyme activity was expressed as nmoles of sulfate conjugated product formed per hr of incubation. Protein concentrations were measured by the dye-binding method of Bradford with bovine serum albumin (BSA) as a standard.
Enzyme thermal stability was determined as described by Reiter and Weinshilboum, [0060] Clin. Pharmacol. Ther., 32:612-621(1982). Specifically, hepatic HSS preparations or platelet preparations were thawed, diluted and were then either subjected to thermal inactivation for 15 min at 44° C. or were kept on ice as a control. In these experiments, heated over control (H/C) ratios were used as a measure of thermal stability. The thermal stability of recombinant proteins was measured by incubating diluted, transfected COS-1 cell HSS for 15 min in a Perkin Elmer 2400 thermal cycler at a series of temperatures. All samples were placed on ice immediately after the thermal inactivation step, and PST activity was measured in both heated and control samples. Thermal inactivation curves were then constructed for each recombinant protein by plotting SULT activity expressed as a percentage of the control value. The concentration of 4-nitrophenol used to assay each of the recombinant proteins was determined on the basis of the results of the substrate kinetic experiments during which apparent K_mvalues had been determined. Those concentrations were: SULT1A1 (*1, *2, *3), 4 μM; SULT1A2, 100 μM; SULT1A2*2, 3 mM; SULT1A2*3, 50 μM; and SULT1A3, 3 mM.
DCNP inhibition was determined by measuring enzyme activity in the presence of a series of DCNP concentrations dissolved in dimethylsulfoxide. Blank samples for those experiments contained the appropriate concentration of DCNP, but no sulfate acceptor substrate. The concentration of 4-nitrophenol used to study each recombinant protein was the same as was used in the thermal stability experiments. All assays for the determination of apparent K[0061] _mvalues, thermal stability or DCNP inhibition were performed in triplicate, and all experiments were performed at least three times, i.e., each of the data points shown subsequently represents the average of at least nine separate assays.
1.3 PCR Amplification and DNA Sequencing [0062]
Total genomic DNA was isolated from the human liver biopsy samples with a QIAamp Tissue Kit (Qiagen, Inc., Chatsworth, Calif.). In addition, genomic DNA was isolated from 150 randomly selected Caucasian blood donors at the Mayo Clinic Blood Blank. Gene-specific primers for the PCR were designed by comparing the sequences of SULT1A1, SULT1A2, and SULT1A3 (Genbank accession numbers U52852, U34804 and U20499, respectively) and identifying intron sequences that differed among the three genes. These gene-specific primers were then used to amplify, in three separate segments for each gene, the coding regions of either SULT1A1 or SULT1A2 (FIG. 2). To assure specificity, an initial long PCR amplification was performed using oligonucleotide primers that annealed to unique sequences present in the 5′-and 3′-flanking regions of each gene. Those long PCR products were then used as templates for the subsequent PCR reactions to amplify coding regions of the genes. Sequences of the PCR primers used to perform these experiments are listed in Table 1. In Table 1, “I” represents “intron”, “F” represents “forward”, “R” represents “reverse” and “D” (“downstream”) represents 3′-flanking region of the gene. [0063]

DNA sequencing was performed with single-stranded DNA as template to help assure the detection of heterozygous samples. To make that possible, single-stranded DNA was generated by exonuclease digestion of either the sense or antisense strand of the double-stranded PCR amplification products. Phosphorothioate groups were conjugated to the 5′-end of either the forward or reverse PCR primer, depending on which of the two strands was to be protected from exonuclease digestion. Specifically, the PCR amplification of gene segments was performed in a 50 μl reaction mixture using Amplitaq Gold DNA polymerase (Perkin Elmer). Digestion of the non-phosphorothioated strand involved incubation of 16 μl of the post-amplification reaction mixture with 20 units of T7 gene 6 exonuclease (United States Biochemical, Cleveland, Ohio) in 10 mM Tris-HCl buffer, pH 7.5, containing 200 μM DTT and 20 μg/ml BSA. This mixture was incubated at 37° C. for 4 hr, followed by inactivation of the exonuclease by incubation at 80° C. for 15 min. The resulting single stranded DNA was used as a sequencing template after PCR primers and salts had been removed with a Microcon-100 microconcentrator (Amicon, Beverly, Mass.). DNA sequencing was performed in the Mayo Clinic Molecular Biology Core Facility with an ABI Model 377 sequencer (Perkin Elmer, Foster City, Calif.) using dye terminator cycler sequencing chemistry.

TABLE 1


PCR Primers

		Seq	PRIMER
REACTION	PRIMER	ID	SEQUENCE (5′ to 3′)

SULT1A1 Gene-Specific Amplifications

Long PCR	1AF(-119)	5	CCTGGAGACCTTCACACACCCTGATA
	DR3296	6	CCACTCTGCCTGGCCCACAATCATA
Segment
1	I1AF11	7	GCTGGGGAACCACCGCATTAGAG
	I4R83	8	AACTCCCAACCTCACGTGATCTG
Segment
2	I4F1018	9	CCTCAGGTTCCTCCTTTGCCAAT
	I6R93	10	TGCCAAGGGAGGGGGCTGGGTGA
Segment
3	I6F395	11	GTTGAGGAGTTGGCTCTGCAGGGTC
	DR3296	12	CCACTCTGCCTGGCCCACAATCATA

SULTIA2 Gene-Specific Amplifications

Long PCR	1AF(-90)	13	GGGCCCCGTTCCACGAGGGTGCTTTCAC
	DR4590	14	TGACCCCACTAGGAAGGGAGTCAGCACCCCTACT
Segment
1	I1AF16	15	GGAACCACCACATTAGAAC
	I4R86	16	TGGAACTTCTGGCTTCAAGGGATCT
Segment
2	I4F1117	17	CCTCAGCTTCCTCCTTTGCCAAA
	I6R81	18	TGGCTGGGTGGCCTTGGC
Segment
3	I6F688	19	GCTGGCTCTATGGGTTTTGAAGT
	DR4094
	20	CTGGAGCGGGGAGGTGGCCGTATT

SULT1A3 Gene-Specific Amplifications

Long PCR	TL F2	21	AATGCCCGCAACAGTGCCTGCTGCATAGAG
	TL R3
	22	ACGCTGCCCGGCGGACTCGACGTCCTCCACCATCTT
Segment
1	I1AF1329	23	GAGAATCCCACTTTCTTGCTGTT
	I4R171	24	GGGAACAGTCTATGCCACCATAC
Segment
2	I4F1308	25	GGTTCCTCCTTTGCCAGTTCAAC
	I6R240	26	GGACTAAGTATCTGATCCGTGG
Segment
3	I6F405	27	GGGCCCCAGGGGTTGAGGCTCTT
	DR3666	28	ATATGTGGCCCCACCGGGCATTC

1.4 COS-1 Cell Expression [0065]
Seven different SULT expression constructs were used to transfect COS-1 cells. These constructs included cDNA sequences for all of the common SULT1A1 and 1A2 allozymes observed during the present experiments, 1A1*1, 1A1*2, 1A1*3, 1A2*1, 1A2*2, and 1A2*3, as well as SULT1A3. As a control, transfection was also performed with expression vector that lacked an insert. All SULT cDNA sequences used to create the expression constructs had either been cloned in our laboratory (SULT1A1*2, SULT1A2*2, SULT1A3), were obtained from the Expressed Sequence Tag (EST) database and American Type Culture Collection (SULT1A1*3, SULT1A2*1) or were created by site directed mutagenesis (SULT1A1*1, SULT1A2*3) Each SULT cDNA was then amplified with the PCR and was subcloned into the eukaryotic expression vector pCR3.1 (Invitrogen, San Diego, Calif.). All inserts were sequenced after subcloning to assure that no variant sequence had been introduced during the PCR amplifications. COS-1 cells were then transfected with these expression constructs by use of the DEAE-dextran method. After 48 hr in culture, the transfected cells were harvested and cytosols were prepared as described by Wood, T. C. et al., [0066] Biochem. Biophys. Res. Commun., 198:1119-1127 (1994). Aliquots of these cytosol preparations were stored at −80° C. prior to assay.
1.5 Data Analysis [0067]
Apparent K[0068] _mvalues were calculated by using the method of Wilkinson with a computer program written by Cleland. Wilkinson, G. N., Biochem. J., 80:324-332 (1961); and Cleland, W. W., Nature, 198:463-365 (1963). IC₅₀values and 50% thermal inactivation (T₅₀) values were calculated with the GraphPAD InPlot program (GraphPAD InPlot Software, San Diego, Calif.). Statistical comparisons of data were performed by ANOVA with the StatView program, version 4.5 (Abacus Concepts, Inc., Berkeley, Calif.). Linkage analysis was performed using the EH program developed by Terwilliger and Ott, Handbook of Human Genetic Linkage, The Johns Hopkins University Press, Baltimore, pp. 188-193 (1994).
2.0 [0069]
The experiments were performed in an attempt to identify common variant alleles for SULT1A1 and SULT1A2, to determine the biochemical and physical properties of allozymes encoded by common alleles for SULT1A2 and SULT1A1 and to determine whether those alleles might by systematically associated with variation in TS PST phenotype in an important drug-metabolizing organ, the human liver. To achieve these goals, a stepwise strategy was utilized that took advantage of the availability of a “bank” of human hepatic biopsy samples which could be phenotyped for level of TS PST activity and thermal stability. DNA sequence information was available for each of the three known human PST genes (SULT1A1, SULT1A2 and SULT1A3). SULT1A1 and SULT1A2 are located in close proximity within a 50 kb region on human chromosome 16. Raftogianis, R. et al., [0070] Pharmacogenetics, 6:473-487 (1996).
All exons for both SULT1A1 and SULT1A2 were sequenced using DNA from 150 platelet samples and 61 hepatic tissue samples to detect nucleotide polymorphisms and to determine whether there were significant correlations between genotypes for SULT1A2 and/or SULT1A1 and TS PST phenotype. [0071]
2.1 SULT1A2 and SULT1A1 Genetic Polymorphisms [0072]
All exons encoding protein for both SULT1A2 and SULT1A1 were PCR amplified in three segments (FIG. 2), and were then sequenced on both strands. Approximately 2 kb of DNA was sequenced for each gene. Therefore, a total of approximately 300 kB and 250 kB of sequence was analyzed for the 150 platelet samples and 61 hepatic biopsy samples, respectively. Thirteen different SULT1A2 alleles were observed among the 122 alleles sequenced in the 61 biopsy samples. These alleles resulted from various combinations of ten different single nucleotide polymorphisms (SNPs) (Table 2A). In Table 2A, numbers at the top indicate the nucleotide position within the ORF, in which 1=the “A” in the “ATG” start codon; or introns, in which an “I” followed by a numeral indicates the location of the nucleotide within the intron (i.e., I2-34 is the 34th nucleotide from the 5′-end of intron 2). Nucleotides shown as white type against a black background alter the encoded amino acid. Nucleotides 895 and 902 lie within the 3′-UTR of the SULT1A2 mRNA. The values shown in the right-hand column indicate allele frequencies in the 61 hepatic biopsy samples. [0073]

Four of the SULT1A2 SNPs altered the encoded amino acid, resulting in six different SULT1A2 allozymes, three of which appeared to be “common” (frequency≧1%, Table 2B). In Table 2B, numbers at the top indicate amino acid position from the N-terminus. The right-hand column indicates allozyme frequencies in the 61 hepatic biopsy samples studies. The other three alleles were observed only once, but their existence was confirmed by independent PCR and sequencing reactions. The allele nomenclature used here assigns different numerals after the * to alleles that encode different allozymes, with a subsequent alphabetic designation for alleles that also differ with regard to “silent” SNPs. Since population data was obtained, numeric assignments were not made randomly, but rather could be assigned on the basis of relative allele frequency in the population sample studied, i.e., *1 was more frequent than *2, *2 was more common than was *3, etc.

TABLE 2A


SULT1A2 ALLELES

					Allozyme
Exon	Exon	Exon	Exon	Frequency
II	VI	VII	VIII	61 Hepatic

	20	24	56	I2-34	I5-78	506	704	I7-9	895	902	Biopsy Samples

*1A	T	T	C	T	T	C	A	C	T	A	0.467
*1B	T	T	C	T	C	C	A	C	T	A	0.025
*1C	T	T	C	C	C	C	A	C	T	A	0.008
*1D	T	T	C	T	C	C	A	C	C	A	0.008
*2A	C	C	C	C	C	C	C	C	C	G	0.262
*2B	C	C	C	T	C	C	C	C	C	G	0.016
*2C	C	C	C	C	C	C	C	T	C	G	0.008
*3A	T	T	T	T	C	C	A	C	T	A	0.156
*3B	T	T	T	T	T	C	A	C	T	A	0.016
*3C	T	T	T	T	C	C	A	T	T	A	0.008
*4	C	C	C	C	C	T	C	C	C	G	0.008
*5	C	C	C	C	C	C	A	C	C	G	0.008
*6	T	T	C	T	T	C	C	C	C	G	0.008

TABLE 2B

SULT1A2 ALLOZYMES

		Allozyme
		Frequency
	Amino Acid	61 Hepatic

Allozyme	7	19	184	235	Biopsy Samples

*1	Ile	Pro	Arg	Asn	0.508
*2	Thr	Pro	Arg	Thr	0.287
*3	Ile	Leu	Arg	Asn	0.180
*4	Thr	Pro	Cys	Thr	0.008
*5	Thr	Pro	Arg	Asn	0.008
*6	Ile	Pro	Arg	Thr	0.008

Thirteen different SULT1A1 alleles were detected in the platelet samples. These alleles encoded four different allozymes for SULT1A1 (Table 3). In Table 3, numbers at the top indicate the nucleotide position within the ORF, in which 1=the “A” in the “ATG” start codon; or introns, in which an “I” followed by a numeral indicates the intron number, and the number after the dash indicates the location of the nucleotide within the intron (i.e., I5-34 is the 34th nucleotide from the 5′-end of the 5th intron). Nucleotides 902 and 973 lie within the 3′-UTR of the SULT1A1 mRNA. The values in the right-hand columns indicate allele frequencies in the 61 hepatic biopsy samples studied or in DNA from 150 randomly selected Caucasian blood donors. [0075]

The 61 liver samples contained 10 of the 13 SULT1A1 alleles identified in platelets, and encoded three of the four SULT1A1 allozymes. Alleles SULT1A1*1G, *1H, *1I, *3A and *4 were not present in these liver samples, but two novel SULT1A1 alleles, *1J and *1K, were detected, bringing the total number of SULT1A1 alleles identified to fifteen. These fifteen alleles involve various permutations of 24 individual SNPs located within the approximately 2 kb of SULT1A1 DNA sequenced (Table 4).

TABLE 3


SULT1A1 SNP
SULT1A1 ALLELES

Exon

11A-

II

III

15-

16-

Allele

138

57

110

153

162

34

35

11

14

17

35

45

64

488

509

*1A

T

G

T

A

C

G

C

T

A

C

A

T

G

*1B

T

G

T

A

C

A

G

C

T

A

G

T

G

*1C

T

A

G

C

G

C

G

C

T

A

C

A

C

A

*1D

C

G

T

A

C

G

C

T

A

C

A

T

G

*1E

T

G

T

A

C

A

G

C

T

A

G

T

G

*1F

C

G

T

A

C

A

G

C

T

A

G

T

G

*1G

T

G

T

A

C

G

C

T

A

G

T

G

*1H

T

A

G

C

G

C

G

C

T

A

C

A

T

G

*1I

T

A

G

T

A

C

G

C

T

A

C

A

T

G

*1J

T

A

G

C

G

C

G

C

T

A

C

A

C

A

*1K

T

G

C

G

C

G

C

T

A

C

A

C

A

*2

T

G

C

G

C

G

C

T

A

C

A

C

A

*3A

T

G

T

A

C

G

C

T

A

C

A

T

G

*3B

T

G

T

A

T

A

G

C

T

A

G

T

G

*4

T

A

T

A

C

A

G

C

T

A

G

T

G

					Allele	Allele
					Frequency	Frequency
Exon				Exon	61 Hepatic	150 Random
VII	17-	17-	17-	VIII	Biopsy	Blood

600

638

645

667

16

69

120

902

973

Samples

Donors

*1A

G

A

C

T

C

A

C

0.328

0.303

*1B

G

A

C

T

C

A

C

0.221

0.237

*1C

C

G

A

C

A

T

0.041

0.040

*1D

G

A

C

T

C

A

C

0.016

0.027

*1E

G

A

C

T

G

A

C

0.016

0.020

*1F

G

A

C

T

C

A

C

0.033

0.017

*1G

G

A

C

T

C

A

C

N.D.

0.010

*1H

G

A

C

A

C

N.D.

0.010

*1I

G

A

C

T

C

A

C

N.D.

0.007

*1J

C

G

A

C

G

T

0.008

N.D.

*1K

C

G

A

C

A

C

0.008

N.D.

*2

C

A

G

A

T

C

G

T

0.311

0.313

*3A

G

C

T

C

A

C

N.D.

0.007

*3B

G

C

T

C

A

C

0.016

0.003

*4

G

A

C

T

C

A

C

N.D.

0.003

The newly discovered alleles for SULT1A2 appeared to be in linkage disequilibrium with alleles for SULT1A1. SULT1A1*1 and *3 were linked to SULT1A2*1 and *3 while SULT1A1*2 was linked to SULT1A2*2. In this analysis, the hypothesis of no association between the two polymorphisms was rejected, but the hypothesis of association was supported with x[0077] ²=53.83 (p<0.0001). Of the 122 sets of 1A1/1A2 alleles sequenced for each gene, only ten displayed discordance. The linkage disequilibrium complicated attempts to determine which of these two gene products might be responsible for phenol SULT phenotype. Therefore, to clarify possible genotype-phenotype correlations for these enzymes, biochemical and physical properties of the proteins encoded by all common alleles for SULT1A1 and SULT1A2 were determined.
2.2 COS-1 Cell Expression of SULT1A1 and SULT1A2 Allozymes [0078]
Expression constructs for each of the common (frequencies≧1%) allozymes for SULT1A1 and SULT1A2 were used to transfect COS-1 cells. Selected biochemical and physical properties of the expressed enzymes were then determined. Those properties included apparent K[0079] _mvalues for the two cosubstrates for the enzyme reaction (4-nitrophenol and PAPS); thermal stability; and sensitivity to inhibition by DCNP. The substrate kinetic experiments were performed in two steps. Initially a wide range of concentrations of 4-nitrophenol that varied over at least three orders of magnitude was tested, followed by detailed study of concentrations close to the apparent K_mvalue for that allozyme. Concentrations of 4-nitrophenol that were used to calculate apparent K_mvalues ranged from 0.02 to 5.0 μM for SULT1A1*1, 1A1*2 and 1A1*3; 0.08 to 10.0 μM for SULT1A2*1 and 1A2*3; 1.0 to 1000 μM for SULT1A2*2; and 3.9 to 3000 μM for SULT1A3. Data from these experiments were then used to construct double inverse plots that were used to calculate apparent K_mvalues (Table 5). The results of the substrate kinetic studies suggested that TS PST phenotype in human liver might be due primarily to the expression of SULT1A1, since optimal conditions for the assay of TS PST activity in the human liver involved the use of 4 μM 4-nitrophenol as a substrate. See, Campbell, N. R. C. et al., Biochem. Pharmacol., 36:1435-1446 (1987). This concentration would be optimal for assay of the activities of allozymes encoded by alleles for SULT1A1, but was below the apparent K_mvalues for all of the SULT1A2 allozymes. Of particular importance for the genotype-phenotype correlation analysis described subsequently is the fact that SULT1A2*2 has a very high apparent K_mvalue for 4-nitrophenol (Table 5).
Apparent K[0080] _mvalues of the recombinant SULTs for PAPS were also determined. In those studies, as well as in the thermal stability and DCNP inhibition experiments, the concentrations of 4-nitrophenol used to perform the assays were 4 μM for SULT1A1*1, *2, and *3; 100 μM for SULT1A2*1; 50 μM for 1A2*3; and 3000 μM for SULT1A2*2 and SULT1A3. These concentrations were based on results of the 4-nitrophenol substrate kinetic experiments and represented the concentration at which maximal activity had been observed for that particular allozyme. Apparent K_mvalues of the recombinant SULT proteins for PAPS are also listed in Table 5. With one exception, those values varied from approximately 0.2 to 1.2 μM. The single exception was SULT1A2*1, with an apparent K_mvalue approximately an order of magnitude lower than those of the other enzymes studied (Table 5). Each value in Table 5 represents the mean±SEM of nine separate determinations.
The thermal stabilities of the seven expressed proteins were also determined and varied widely. The rank order of the thermal stabilities was 1A2*2>1A2*1>>1A1*1≅1A1*3≅1A2*3>1A1*2>>1A3 (Table 5). These observations were consistent with experiments described herein that indicated that SULT1A1*2 was associated with a “thermolabile” phenotype in the platelet (FIG. 1) since that allele had the lowest T[0081] ₅₀value of the recombinant “TS-PST-like” allozymes studied (Table 5). It is unlikely that allozyme SULT1A2*2 could explain a “thermolabile” phenotype since it was the most “thermostable” of the allozymes studied.

Finally, sensitivity of the recombinant proteins to inhibition by DCNP was determined. Sixteen different concentrations of DCNP, ranging from 0.01 to 1000 μM, were tested with each recombinant allozyme. IC ₅₀values for DCNP also varied widely, with SULT1A2*3 being most, and SULT1A3 least sensitive to inhibition (Table 5). After all of these data had been obtained, the final step in this series of experiments was an attempt to correlate human liver TS PST phenotype with SULT1A1 and/or SULT1A2 genotype.

TABLE 5


RECOMBINANT HUMAN SULT BIOCHEMICAL AND PHYSICAL
PROPERTIES

Thermal

DCNP

Apparent Km (μM)

Stability

Inhibition

Allozyme	4-Nitrophenol	PAPS	T₅₀(° C.)	IC₅₀(μM)

SULT1A1
*1	0.88 ± 0.07	1.21 ± 0.02	39.3 ± 0.64	1.44 ± 0.11
*2	0.78 ± 0.08	0.98 ± 0.03	37.2 ± 0.43	1.38 ± 0.28
*3	0.31 ± 0.01	0.17 ± 0.02	38.9 ± 0.03	1.32 ± 0.27
SULT1A2
*1	8.70 ± 1.10	0.05 ± 0.001	43.6 ± 0.15	6.94 ± 0.55
*2	373 ± 33	0.50 ± 0.001	46.3 ± 0.09	44.4 ± 1.50
*3	5.65 ± 1.14	0.28 ± 0.006	38.8 ± 0.19	0.97 ± 0.001
SULT1A3	4960 ± 810	0.28 ± 0.001	32.6 ± 0.19	86.9 ± 6.00

2.3 Human Liver Genotype-Phenotype Correlation [0083]

TS PST activity and thermal stability was measured in human platelet samples (n=905) and human liver biopsy samples (n=61). A scattergram of these data are shown in FIGS. 1 and 2. Subjects homozygous for the allele SULT1A1*2 uniformly had low levels of both TS PST activity and thermal stability in their platelets (FIG. 1B). The genotype-phenotype correlation for SULT1A1 in the liver samples is shown in FIG. 4A. Similar data for SULT1A2 are plotted in FIG. 4B. FIG. 4 demonstrates that the SULT1A1*2 allele appeared to be associated with low TS PST thermal stability in the liver, just as it was in the human blood platelet (FIG. 1B). For example, the average H/C ratio for samples homozygous for SULT1A1*1 was 0.57±0.01 (n=28, mean±SEM), while that for heterozygous 1A1*1/1A1*2 samples was 0.40±0.01 (n=24) and that for samples homozygous for SULT1A1*2 was 0.18±0.01 (n=7, p<0.001 by ANOVA). Table 6 summarizes this data.

TABLE 6


SULT1A1 ALLOZYMES AND TS PST ACTIVITY

Allozyme	AA 213	N	H/C Ratio	N	TS PST activity

Platelet
1/1	Arg/Arg	11	0.62 ± 0.03**	11	1.08 ± 0.25
1/2	Arg/His	8	0.53 ± 0.03**	9	0.90 ± 0.20
2/2	His/His	13	0.09 ± 0.02**	13	0.14 ± 0.01
Liver
1/1	Arg/Arg	28^a	57.5 ± 1.31*	28^a	56.0 ± 3.05
1/2	Arg/His	24	40.5 ± 1.38*	24	56.8 ± 4.19
2/2	His/His	7	17.7 ± 1.44*	3^b	28.5 ± 2.27**

[0085]
Although the SULT1A1*2 allele was highly correlated with low TS PST thermal stability in the liver, unlike the situation in the platelet, low thermal stability was not significantly correlated with low levels of TS PST activity (FIG. 4A). Of possible importance is the fact that, when the data were stratified on the basis of diagnosis, of the seven samples homozygous for SULT1A1*2, the three from patients with benign hepatic disease had the lowest levels of TS PST activity, while the four samples from patients with malignant disease had the highest activity (28.5±2.3 vs. 59.8±4.0, mean±SEM respectively, p<0.002). [0086]
The results of the substrate kinetic experiments (Table 5), as well as the results of the thermal stability studies suggested that TS PST phenotype in the liver was most likely a measure of SULT1A1 expression. As pointed out previously, that was true because both K[0087] _mvalues for 4-nitrophenol and T₅₀values for recombinant SULT1A2 allozymes were above those found to be optimal for the determination of TS PST phenotype in human liver cytosol preparations (Table 5). Testing that hypothesis directly is complicated by the fact that SULT1A1 and 1A2 share 95% or greater identity for both protein amino acid and mRNA nucleotide sequences; so neither Western nor Northern blots can easily distinguish between them. However, biochemical studies of recombinant SULT allozymes suggested that the sulfation of 100 μM 4-nitrophenol might represent a relatively specific measure of SULT1A2 activity (Table 5). As a result of the profound substrate inhibition which these enzymes display, SULT1A1 allozymes show little or no activity at that concentration, and SULT1A3 would not contribute significantly to activity measure at that concentration because of its very high K_mvalue for 4-nitrophenol (Table 6). Therefore, 100 μM 4-nitrophenol was used as a substrate with cytosol from six pooled liver samples in an attempt to measure SULT1A2 activity. However, after three attempts no activity was detected, suggesting that SULT1A2 is not highly expressed in the liver. Ozawa, S. et al., Chem. Biol. Interact., 109:237-248 (1998).
In summary, common genetic polymorphisms were observed for both SULT1A1 and SULT1A2 in humans. However, the proteins encoded by these alleles differed in their biochemical and physical properties. Recombinant SULT1A2*2 had a K[0088] _mvalue dramatically higher than did SULT1A2*1 or 1A2*3. The allele SULT1A1*2 was associated with decreased TS PST thermal stability in the liver and in the blood platelet. Unlike the situation in the platelet, SULT1A1 or SULT1A2 alleles identified in the hepatic tissues did not appear to be systematically associated with level of TS PST activity.
2.4 SULT1A3 Polymorphisms [0089]
All exons and introns for SULT1A3 were sequenced using DNA from 150 random blood donor samples to detect nucleotide polymorphisms. Table 7 describes sequence variants. [0090]

TABLE 7

Nucleotide Transition/Transversion and

Position Within SULT1A3 Gene

Exon

3 I3-83/84

Classification 105 Insertion I4-69 I6-69 I7-113

Wild Type A — G G G

Variant G CAGT A A T

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. [0091]

0

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 52

<210> SEQ ID NO 1

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 1

ccacggtctc ctctggcagg ggg 23

<210> SEQ ID NO 2

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 2

gttgaggagt tggctctgca gggtc 25

<210> SEQ ID NO 3

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 3

cacgtactcc agtggcgggc cctag 25

<210> SEQ ID NO 4

<211> LENGTH: 18

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 4

ggaaccacca cattagaa 18

<210> SEQ ID NO 5

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 5

cctggagacc ttcacacacc ctgata 26

<210> SEQ ID NO 6

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 6

ccactctgcc tggcccacaa tcata 25

<210> SEQ ID NO 7

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 7

gctggggaac caccgcatta gag 23

<210> SEQ ID NO 8

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 8

aactcccaac ctcacgtgat ctg 23

<210> SEQ ID NO 9

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 9

cctcaggttc ctcctttgcc aat 23

<210> SEQ ID NO 10

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 10

tgccaaggga gggggctggg tga 23

<210> SEQ ID NO 11

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 11

gttgaggagt tggctctgca gggtc 25

<210> SEQ ID NO 12

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 12

ccactctgcc tggcccacaa tcata 25

<210> SEQ ID NO 13

<211> LENGTH: 28

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 13

gggccccgtt ccacgagggt gctttcac 28

<210> SEQ ID NO 14

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 14

tgaccccact aggaagggag tcagcacccc tact 34

<210> SEQ ID NO 15

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 15

ggaaccacca cattagaac 19

<210> SEQ ID NO 16

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 16

tggaacttct ggcttcaagg gatct 25

<210> SEQ ID NO 17

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 17

cctcagcttc ctcctttgcc aaa 23

<210> SEQ ID NO 18

<211> LENGTH: 18

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 18

tggctgggtg gccttggc 18

<210> SEQ ID NO 19

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 19

gctggctcta tgggttttga agt 23

<210> SEQ ID NO 20

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 20

ctggagcggg gaggtggccg tatt 24

<210> SEQ ID NO 21

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 21

aatgcccgca acagtgcctg ctgcatagag 30

<210> SEQ ID NO 22

<211> LENGTH: 36

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 22

acgctgcccg gcggactcga cgtcctccac catctt 36

<210> SEQ ID NO 23

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 23

gagaatccca ctttcttgct gtt 23

<210> SEQ ID NO 24

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 24

gggaacagtc tatgccacca tac 23

<210> SEQ ID NO 25

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 25

ggttcctcct ttgccagttc aac 23

<210> SEQ ID NO 26

<211> LENGTH: 22

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 26

ggactaagta tctgatccgt gg 22

<210> SEQ ID NO 27

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 27

gggccccagg ggttgaggct ctt 23

<210> SEQ ID NO 28

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 28

atatgtggcc ccaccgggca ttc 23

<210> SEQ ID NO 29

<211> LENGTH: 7152

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (3810)...(3956)

<221> NAME/KEY: CDS

<222> LOCATION: (4061)...(4186)

<221> NAME/KEY: CDS

<222> LOCATION: (4276)...(4374)

<221> NAME/KEY: CDS

<222> LOCATION: (5584)...(5709)

<221> NAME/KEY: CDS

<222> LOCATION: (5805)...(5900)

<221> NAME/KEY: CDS

<222> LOCATION: (6426)...(6605)

<221> NAME/KEY: CDS

<222> LOCATION: (6728)...(6837)

<400> SEQUENCE: 29

ttgctgccag ctgcctctcc ctccttgtct cttacctgcc tgctgcctgg gacaggatga 60

agcggggccc ttgtgttgcc ccaaccctgg ctgttggcta agagcccacg tgatctgcct 120

gtgagaggag ttccttccgg aagaaccagg gcagcttctg cccctagagg gccaatgccc 180

tagctgagtg cagtcccccg gccccagcct ggtccagctt tgggaagagg gtgcccagtt 240

gtgcaatcca ggccggggca gccgtgtcct gatcttggta ttcagggctg agcctggagg 300

gggcttgtga tgcctgactc tgtctccctc tctggcccca tgccttggta gctgtgaggc 360

gtcactgctt tgggtgacct gatctggctg tgatggatga gcacggggga aatagtggaa 420

gactcggaat tagaagacgt gagtgggctt tggccccagc ctccctaccc cactccctgt 480

cctgggctgc ctgtgaccaa cctcgtttct gcaggcacac tggatagccc tgctggagct 540

cagtgtccct aatcccctcc agatactggt ggcctagggg aggtcatcaa aaaccggtgg 600

gacatcgacc tcagcccgtt tccacgcttt tttttgtttt tttttttttt ttgagaccga 660

gtttcactct tgttgcccag gctggagtgc aatggcgtga tcttggctca ccgcaacctc 720

cgcctcctgg gttcaagcga ttctcctgcc tcagcctccc aagtagctgg gattccaggc 780

gtgtgccacc aggcttgact aattttctat ttttagtaga gacaaggttt ctccatgttg 840

gtcaggctgg tctcaaactc ccgacttcag gtgatctgcc tgcctcggcc ccccaaagtg 900

ctgggattac aggagtgagc caccgtgcca ggccttctcc aggctcttgg caccttagcc 960

agaaacaatt taaggacaag tgcaaaagtc atgaatgtag gcagatttcc tgcagagtaa 1020

agggactcac tcaagaagag gaacgtgggg gtcctcaaga gagtgtctca tgccctacaa 1080

ggtgtggggc tgacctttat gggcttcttc aactaaagag gggtatattc atgaagagtc 1140

caggaaaagg taaagatttc tcaagaccgt ggtgccacaa tttacaccca aatacaggtg 1200

ttcctggagc cgtcttggca ctggtgggtg tacggtttca tatgttactg atcatacaat 1260

gagatcctag gtgaaaccta catcaaatac agcgccatgt tgtgtctggt tggtcgtggc 1320

cagcttggtc ctcatcctat ttttcaggga cttattggcc cttagcgcat gcagctattt 1380

caagtttcct tcttctcctc atgtgaaact gctgcctggg attttgtatt cacttgctac 1440

cactctatta atctcacatt ctcgcctctt ttctgtgtca ccccgtgtgg gtccgacagg 1500

ttgttactag agtgcaatac aaagtcttag tcaagggaac ctcctgaggg ttgctgaggg 1560

caggggtgga gctagtagcc tgaggacctg ccagtcacgg ggattcctca tgggcacaga 1620

ggagggagga ggggtccatg gccctagcat atgagaagcc tctcctctgc ctggaattcc 1680

catgcctcag cttcccccac actcccacct gtccgcttgc ctctgaactc acgcatttct 1740

tggaagtctt gggagattca cctttactca gatggttgtt tacctgtctc gtgcacagct 1800

tgaccttgga ctttaaagtg aggataaaga acgaggagga tggggggatg ccccccttcc 1860

acgggccctg tggcttccaa acctcggcct cctctggtct cttgtctgtg gagcctcctt 1920

caaacccagg gaaataaaac cacctgccac gggttgtggt tcttctagga tcttctatca 1980

atgttctctg aggtccccag gagccatgaa gctggggctg actcccaggg caatgggact 2040

gcagtgtcct tgttctttct tgttctatgc atccatgctc tgctccaccc ctgccccttc 2100

actctgccca cacacatccc tctagactgg ccttgtggtc agagcctgga gtgcatgggc 2160

tgctgggggc ctgtgggctg cactgggcca gaacccctgg caccttcaag actggcctgg 2220

agccagcagg taggtgacct ttccagggcc tgcctatccc agctttctcc tccaatccct 2280

cccctctctt gcctgggtca attagagaga gcttgtctgt tggctgcctg gcggggtgga 2340

gttcaggggc aggtcaggag cccagtgaca gctcggaaaa aaaaaaaaaa aaaaaaaaaa 2400

cagaaaaaaa aacctacaaa aacaaaccca ccattgggcc tttccccttt cattcttctg 2460

ttttctacac agcaaactca gtcgtggctt tggagatcac tttaagcttg tctccagctg 2520

gcacactaag gagggtaatg gagaagctcc cccaccccca accccacccc ttccttccgg 2580

aagcaaatct aagtccagcc ccggctccag atccctccca cagtggacct aggaaaccct 2640

cagctcagag aacaaccctg cattccccac acagcaccca caatcagcca ctgcgggcga 2700

ggagggcacg aggccaggtt cccaagagct caggtgagtg acacagtgga acggcccagg 2760

gcgccctcac cctgctcagc ttgtggctct aacattccag aagctgaggc ctctggcatc 2820

cctgcccttt ccccatggat atcccatttc agacaaccct ggcctgcgtg aatccccctc 2880

ccttcccttg tttgtttgtt tttttccccg ggggaggcca ggtcttgctg tcacccaggc 2940

tggagtgctg tgggatcctg gccactgcag ccttgaattc ctgggctcaa gtgattctct 3000

tgccacagcc tctggagtag ctaggactac aggccctcat catcctgcct ggttaatgtt 3060

taagaatttt tttaaagatt tttagagatg gggtcttgca atgctgcacc aggttggtct 3120

ccaactcctg gcctcagcct ccctagggtc tgggattata ggtgggagcc accctgccta 3180

ggcctgtgct tttgctgagt catcagagtt ttgttcattc ccacagcagc tctggcccct 3240

agtagcagct cagttcctca atgggccgtg tttgtcctgg agcccagatg gactgtggcc 3300

aggcaagtgg atcacaggcc tggctggcct gggcggtttc cacatgtgag gggctgaggg 3360

gctcaaggag gggagcatct ccactgggtg gaggctgggg gtcccagcag gaaatggtga 3420

gacaaagggc gctggctggc agggagacag cacaggaagg tcctagagct tcctcagtgc 3480

agctggactc tcctggagac cttcacacac cctgatatct gggccttgcc cgacgagggt 3540

gctttcactg gtctgcacca tggcccaggc cctgggattt tgaacagctc cgcaggtgaa 3600

tgaaaggtga ggccaggctg gggaaccacc gcattagagc ccgacctggt tttcagcccc 3660

agccccgcca ctgactggct ttgtgagtgc gggcaagtca ctcagcctcc ctaggcctca 3720

gtgacttccc tgaaagcaag aattccactt tcttgctgtt gtgatggtgg taagggaacg 3780

ggcctggctc tggcccctga cgcaggaac atg gag ctg atc cag gac acc tcc 3833

Met Glu Leu Ile Gln Asp Thr Ser

1 5

cgc ccg cca ctg gag tac gtg aag ggg gtc ccg ctc atc aag tac ttt 3881

Arg Pro Pro Leu Glu Tyr Val Lys Gly Val Pro Leu Ile Lys Tyr Phe

10 15 20

gca gag gca ctg ggg ccc ctg cag agc ttc cag gcc cgg cct gat gac 3929

Ala Glu Ala Leu Gly Pro Leu Gln Ser Phe Gln Ala Arg Pro Asp Asp

25 30 35 40

ctg ctc atc agc acc tac ccc aag tcc ggtaagtgag gagggccacc 3976

Leu Leu Ile Ser Thr Tyr Pro Lys Ser

45

caccctctcc caggtggcag tccccacctt ggccagcgag gtcgtgccct cagcctgctc 4036

accccccatc tccctccctc tcca ggc acc acc tgg gtg agc cag att ctg 4087

Gly Thr Thr Trp Val Ser Gln Ile Leu

50 55

gac atg atc tac cag ggt ggt gac ctg gag aag tgt cac cga gct ccc 4135

Asp Met Ile Tyr Gln Gly Gly Asp Leu Glu Lys Cys His Arg Ala Pro

60 65 70

atc ttc atg cgg gtg ccc ttc ctt gag ttc aaa gcc cca ggg att ccc 4183

Ile Phe Met Arg Val Pro Phe Leu Glu Phe Lys Ala Pro Gly Ile Pro

75 80 85 90

tca ggtgtgtgag tgtgtcctgg gtgcaagggg agtggaggaa gacagggctg 4236

Ser

gggcttcagc tcaccagacc ttccctgacc cactgctca ggg atg gag act ctg 4290

Gly Met Glu Thr Leu

95

aaa gac aca ccg gcc cca cga ctc ctg aag aca cac ctg ccc ctg gct 4338

Lys Asp Thr Pro Ala Pro Arg Leu Leu Lys Thr His Leu Pro Leu Ala

100 105 110

ctg ctc ccc cag act ctg ttg gat cag aag gtc aag gtgaggcagg 4384

Leu Leu Pro Gln Thr Leu Leu Asp Gln Lys Val Lys

115 120

gcacagtgtt tcacatccat aatcccagca ctttgggagg ctgaggcagg cagatcacct 4444

gaggttggga gtttgagagc accctgagca acatagaaga accttgtctc tactaaaaat 4504

acagaattag ccgggtgtgg tggcgggtgc ctgtaatccc agctactccg aagcctgaga 4564

caggagaatc acttgaaccc gggagaagga ggttgtggtg agccagagat cccaccattg 4624

cattccagcc tgagcaacaa gagcaaaact cacaaaaata aataaataaa tagatatata 4684

aataaaaata aaactgtggc acctgtggtg gctcactgct gtaatgccag cactttggga 4744

ggccaaattg ggtggatcac ttgagctcag gagttacaga ccagcccggg aaacatgggg 4804

aacttccatc tctataaaaa tgcaaaatat cagcagggca tggtggcatg gcgctgtagt 4864

tccagctact ggaaagtctg aggttggagg attgcttgag cctgggaggt caaggttgca 4924

gtgagttatt atcactccag tgcactccaa cctgggcgac agaaaaaaag aaagaccaag 4984

gtcttttttc ttttttgaga ttgtctcaat aaataaataa atgaataaat aaaaataaaa 5044

taaagtaaaa taaatcccac aattaaaaga aaaagcaaag gtccaggtgt ggggcatgtg 5104

aatccaggga aggaggccct ggctcagccc agctttggtc ctgttcttct gggaaagtcg 5164

cctcacttcc tccagccttg tctcatcttc tgcggcgggg actgtctgcc tcttgctctg 5224

atgaccaaga acgtaaggct cttcagtgta gacctaagaa agctagaggg tgggtcctca 5284

caggcccaca aaatttggtg gcggtgggat cacggctggt ggagcgtgcc ttgctccaga 5344

tcggggtgtg acgcattgat gcagattata ttgctataga atatgatggt ctcagggacc 5404

aggcaggact ttggcttctg agcagggttc agatcctgac ttggccctac cggtgccgtg 5464

agatctcaaa caagtcagcc tctaagcctc aggttcctcc tttgccaatc caagagatga 5524

gctggcctgg ggcaggctgt gtggtgatgg tgctggggtt gagtcttctg cccctgcag 5583

gtg gtc tat gtt gcc cgc aac gca aag gat gtg gca gtt tcc tac tac 5631

Val Val Tyr Val Ala Arg Asn Ala Lys Asp Val Ala Val Ser Tyr Tyr

125 130 135 140

cac ttc tac cac atg gcc aag gtg cac cct gag cct ggg acc tgg gac 5679

His Phe Tyr His Met Ala Lys Val His Pro Glu Pro Gly Thr Trp Asp

145 150 155

agc ttc ctg gag aag ttc atg gtc gga gaa ggtgggtttg atgggaggaa 5729

Ser Phe Leu Glu Lys Phe Met Val Gly Glu

160 165

ggaaagtgtg gagccgaggg gtggtggcta caacgcacag caaccctgtg ttggcacccc 5789

ttgcctgctt ctcca gtg tcc tac gga tcc tgg tac cag cac gtg cag gag 5840

Val Ser Tyr Gly Ser Trp Tyr Gln His Val Gln Glu

170 175

tgg tgg gag ctg agc cgc acc cac cct gtt ctc tac ctc ttc tat gaa 5888

Trp Trp Glu Leu Ser Arg Thr His Pro Val Leu Tyr Leu Phe Tyr Glu

180 185 190

gac atg aag gag gtgagaccac ctgtgaagct tccctccatg tgacacctgg 5940

Asp Met Lys Glu

195

gggccggcac ctcacaggga cccaccaggg tcacccagcc ccctcccttg gcagccccca 6000

cagcaggccc ggattcccca tcctgccttc ttggcccagg cctccccgct acaggcccca 6060

cctggcagcg ggccccacac ggctctcatc acccacatct gagtcagctg catggggggc 6120

cacggatcag aaacttagtc ctattgctac tccctgccaa agggtgtgcc acccagggcc 6180

acagtcatgg aagaagacca tcacggtcct cacccatagg agccaagccc agctcatgat 6240

gggatcacag ggcagacagc aattcttttt acccccggga ctggggccct gggggttgag 6300

gagttggctc tgcagggtct ctaggagagg tggccagatc gcctctgagg ttagagaagg 6360

ggaccccttt tacttttcct gaatcagcaa tccgagcctc cactgaggag ccctctgctg 6420

ctcag aac ccc aaa agg gag att caa aag atc ctg gag ttt gtg ggg cac 6470

Asn Pro Lys Arg Glu Ile Gln Lys Ile Leu Glu Phe Val Gly His

200 205 210

tcc ctg cca gag gag acc gtg gac ttc atg gtt cag cac acg tcg ttc 6518

Ser Leu Pro Glu Glu Thr Val Asp Phe Met Val Gln His Thr Ser Phe

215 220 225

aag gag atg aag aag aac cct atg acc aac tac acc acc gtc ccc cag 6566

Lys Glu Met Lys Lys Asn Pro Met Thr Asn Tyr Thr Thr Val Pro Gln

230 235 240 245

gag ttc atg gac cac agc atc tcc ccc ttc atg agg aaa ggtgggtgct 6615

Glu Phe Met Asp His Ser Ile Ser Pro Phe Met Arg Lys

250 255

ggccagtacg ggggtttggg gcgggtggga gcagcagctg cagcctcccc ataggcactc 6675

ggggcctccc ctgggatgag actccagcct tgctccctgc cttccccccc ca ggc atg 6733

Gly Met

260

gct ggg gac tgg aag acc acc ttc acc gtg gcg cag aat gag cgc ttc 6781

Ala Gly Asp Trp Lys Thr Thr Phe Thr Val Ala Gln Asn Glu Arg Phe

265 270 275

gat gcg gac tat gcg gag aag atg gca ggc tgc agc ctc agc ttc cgc 6829

Asp Ala Asp Tyr Ala Glu Lys Met Ala Gly Cys Ser Leu Ser Phe Arg

280 285 290

tct gag ct gtgagagggg ctcctggggt cactgcagag ggagtgtgcg aatcaaacct 6887

Ser Glu

gaccaagcgg ctcaagaata aaatatgaat tgagggcctg ggacggtagg tcatgtctgt 6947

aatcccagca atttggaggc tgaggtggga ggatcatttg agcccaggag ttcgagacca 7007

acctgggcaa catagtgaga ttctgttaaa aaaataaaat aaaataaaac caatttttaa 7067

aaagagaata aaatatgatt gtgggccagg catagtggct catgcctgta atcccagcaa 7127

tttgagaagt tgaggctaga ggatc 7152

<210> SEQ ID NO 30

<211> LENGTH: 49

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 30

Met Glu Leu Ile Gln Asp Thr Ser Arg Pro Pro Leu Glu Tyr Val Lys

1 5 10 15

Gly Val Pro Leu Ile Lys Tyr Phe Ala Glu Ala Leu Gly Pro Leu Gln

20 25 30

Ser Phe Gln Ala Arg Pro Asp Asp Leu Leu Ile Ser Thr Tyr Pro Lys

35 40 45

Ser

<210> SEQ ID NO 31

<211> LENGTH: 42

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Gly Thr Thr Trp Val Ser Gln Ile Leu Asp Met Ile Tyr Gln Gly Gly

1 5 10 15

Asp Leu Glu Lys Cys His Arg Ala Pro Ile Phe Met Arg Val Pro Phe

20 25 30

Leu Glu Phe Lys Ala Pro Gly Ile Pro Ser

35 40

<210> SEQ ID NO 32

<211> LENGTH: 33

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 32

Gly Met Glu Thr Leu Lys Asp Thr Pro Ala Pro Arg Leu Leu Lys Thr

1 5 10 15

His Leu Pro Leu Ala Leu Leu Pro Gln Thr Leu Leu Asp Gln Lys Val

20 25 30

Lys

<210> SEQ ID NO 33

<211> LENGTH: 42

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 33

Val Val Tyr Val Ala Arg Asn Ala Lys Asp Val Ala Val Ser Tyr Tyr

1 5 10 15

His Phe Tyr His Met Ala Lys Val His Pro Glu Pro Gly Thr Trp Asp

20 25 30

Ser Phe Leu Glu Lys Phe Met Val Gly Glu

35 40

<210> SEQ ID NO 34

<211> LENGTH: 32

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 34

Val Ser Tyr Gly Ser Trp Tyr Gln His Val Gln Glu Trp Trp Glu Leu

1 5 10 15

Ser Arg Thr His Pro Val Leu Tyr Leu Phe Tyr Glu Asp Met Lys Glu

20 25 30

<210> SEQ ID NO 35

<211> LENGTH: 60

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 35

Asn Pro Lys Arg Glu Ile Gln Lys Ile Leu Glu Phe Val Gly His Ser

1 5 10 15

Leu Pro Glu Glu Thr Val Asp Phe Met Val Gln His Thr Ser Phe Lys

20 25 30

Glu Met Lys Lys Asn Pro Met Thr Asn Tyr Thr Thr Val Pro Gln Glu

35 40 45

Phe Met Asp His Ser Ile Ser Pro Phe Met Arg Lys

50 55 60

<210> SEQ ID NO 36

<211> LENGTH: 36

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 36

Gly Met Ala Gly Asp Trp Lys Thr Thr Phe Thr Val Ala Gln Asn Glu

1 5 10 15

Arg Phe Asp Ala Asp Tyr Ala Glu Lys Met Ala Gly Cys Ser Leu Ser

20 25 30

Phe Arg Ser Glu

35

<210> SEQ ID NO 37

<211> LENGTH: 8397

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (3730)...(3879)

<221> NAME/KEY: CDS

<222> LOCATION: (3987)...(4112)

<221> NAME/KEY: CDS

<222> LOCATION: (4198)...(4293)

<221> NAME/KEY: CDS

<222> LOCATION: (6088)...(6213)

<221> NAME/KEY: CDS

<222> LOCATION: (6309)...(6404)

<221> NAME/KEY: CDS

<222> LOCATION: (7214)...(7393)

<221> NAME/KEY: CDS

<222> LOCATION: (7516)...(7629)

<400> SEQUENCE: 37

ctctccctcc ttgtctctta cctgcctgct gcctgggaca ggatgaagcg gggcccttgt 60

gttgccccaa ccctggctgt tggctaagag cccacgtgat ctgcctgtga gaggagttcc 120

ttccggaaga accagggcag cttctgcccc tagagggcca atgccctagc tgagtgcagt 180

cccccggccc cagcctggtc cagctttggg aagagggtgc ccagttgtgc aatccaggcc 240

ggggcagccg tgtcctgatc ttggtattca gggctgagcc tggagggggc ttgtgatgcc 300

tgactctgtc tctctctctg gccccatgcc ttggtagctg tgaggcgtca ctgctttggg 360

tgacctgatc tggctgtgat ggatgagcac gggggaaata gtggaagact cggaattaga 420

agacgtgagt gggctttggc cccagcctcc ctaccccact ccctgtcctg ggctgcctgt 480

gaccaacctt gtttctgcag gcacactgga tagccctgct ggagctcagt gtccctaatc 540

ccctccagat actggtggcc taggggaggt catcaaagac cagtgggaca tcgacctcag 600

cctgtttcca cgtttcttgt tgtttttttt tttttgtgga gacagagttt cactcttgtt 660

gcccaggctg gagtgcaatg gcgtgatctt ggctcaccgc aacctctgcc tcccgggttc 720

aagcgattct cctgcctcag cctcccaagt agctgggatt acaggcgtgt gccaccaggc 780

ttgactaatt ttctattttt agtagagaca aggtttctcc atgttggtca ggctggtctc 840

aaactcccga cttcaggtga tctgcctgcc tcggcctccc aaagtgctgg gattacagga 900

gtgagccacc gtgccaggcc ttctccaggc tcttggcacc ttagccagaa acaatttaag 960

gacaagtgca aaagtcatga acgtaggcag atttcctgca gagtaaaggg actcactgaa 1020

gaagaggaac gtgggggtcc tcaagagagt gtctcatgcc ctacaaggtg tggggctgac 1080

ctttatgggc ttcttcaact aaagaggggt atattcatga agagtccagg aaaaggtaaa 1140

gatttctcaa gaccgtggtg ccacaattta cacccaaata caggtgttcc tggagccgtc 1200

ttggcactgg tgggtgtacg gtttcatatg ttactgattg tacagtgaga tcctaggtga 1260

aacctacatc aaatacagcg ccatgttgct tctggttggt cgcagccagc ttggtcctca 1320

tcctattttt cagggactta ttggcccttg gcacatgcag ctatttcaag tttccttctt 1380

ctggtcatgt gaaactgctg cctgggattt tctgttgtct tgctagcact ctattaatct 1440

cacattctcg cctcttttct gtgccacccc ctgctggtcc ggctggtttt cactagagtg 1500

caatacaaag tctcagtcaa gagggcctcc tgaaggttgc tgagggcagg ggtggagcta 1560

gtagccggag gacctgccag tcatggggat tcctcagggg cacagaggag ggaggagggg 1620

cctgtggccc tagcagggga gcagcctctc ctctgcctgg aaatcccatg cctcagtttt 1680

ccccgcttgc ctctgagctc acgcaaccct gggaaggctt gggagactca cctttactca 1740

gatggttgtt tacctgtctc gtgcccaggt tgaccctgga ctttaaatag tgaggacaaa 1800

gaacgaggag ggtgggggga tgcactcctt ccacgggggc ctgtggcttc caagcctcaa 1860

cctcctctgg tctctgtctg tggagcctcc ttcaaaccca tggaaagaaa agtacctgcc 1920

aggggctgtg gttcttctag gatcttctat cgatgttctg tgaggtcccc agggagccat 1980

gaagctgggg ctggctccca gggcaatggg actgcagtgt ccttgttctt tcttggttct 2040

atggatccat gctctgctcc acccctgccc cttcactctg cccacacgca tcactccaga 2100

ctggccttgt ggtcagagcc tggagtgcat gggctgctgg aggcctgtgg gttgcactgg 2160

gccaggaccc ctggcacctt caagactggc ctggagccag caggtaggtg acctttccag 2220

ggcctgccta tcccagcttt ctcctccaat ccctcccctc tcttgcctgg gtcaattaga 2280

gaaagcttgt cttttggagt tcaggggcag gtcaggagcc cagtgacagc tcaaaaaaaa 2340

aaccccaaaa aaaaaacccc accattgggc cctttcccct ttcattcttc tgttttctac 2400

acaccaaacc cagtcgtggc tttggagatc actttaagct tgtctccagc tggcaaacta 2460

aggagggtaa tagagaagct cccccacccc caaccctacc ccttccttcc ggaagcaaat 2520

ctaagtccag ccccggctcc agatccctcc cacactgacc taagaaaccc tcagcacaga 2580

caacacccct gcattcccca cacaacaccc acactcagcc actgcgggcg aggagggcac 2640

gaggccaggt tcccaagagc tcaggtgagt gacacaccgg aatggcccag gacgccctca 2700

ccctgctcag cttgtggctc caacattcca gaagccgagg cctctgttat ctctgccctc 2760

tccccatgga tatcccattt cagacaaccc cggccggcct gaatccccct cccttccttt 2820

ttttttttcc ggggaggcca ggtcttgctg tcaccgaggc tggagtgctg tgggatcctg 2880

gccactgcag ccttgaattc ctgggctcaa gtgattctcc tgcctcagta gctaggacta 2940

cagaccctca ccatcctgcc tggatagttt taaaaaatat ttttaaaaga tttttagaga 3000

tggggtcttc caatgctgcc cagattggtc tccaaattct ggcctcagcc tccctagggt 3060

ctgggattac aggtgggagc caccctgccc aggatcctcc ttttgctgag tcatcacagt 3120

tttgctcatt cccacatcag gctctggccc ccaataccag ctcagttgct caatgggctg 3180

tttgtcctgg aacccagatg gactgtggcc gggcaagtgg atcacaggcc tggccagcct 3240

aggagttgcc acatgtgagg ggccgagggg ctcaaggagg ggaacatcgg ggagaggagc 3300

ctactgggtg gaggctgggg gtcccagcag gaaatggtga gacaaagggc gctggctggc 3360

aggaagacag cacaggaagg tcctagaggt tcctcagtgc agctggactc tcctggagac 3420

cttcacacac cctgacatct gggccccgtt ccacgagggt gctttcactg gtctgcacca 3480

tggcccaggc cctgggattt tgaacagctc cgcaggtgaa tgaaaggtga ggccaggctg 3540

gggaaccacc acattagaac ccgacctggt tttcagcccc agccccgcca ctgactggcc 3600

ttgtgagtgc gggcaagtca ctcaacctcc ctaggcctca gtgacttccc tgaaagcaag 3660

aattccactt tcttgctgtt gtgatggtgg taagggaacg ggcctggctc tggcccctga 3720

cgcaggaac atg gag ctg atc cag gac atc tct cgc ccg cca ctg gag tac 3771

Met Glu Leu Ile Gln Asp Ile Ser Arg Pro Pro Leu Glu Tyr

1 5 10

gtg aag ggg gtc ccg ctc atc aag tac ttt gca gag gca ctg ggg ccc 3819

Val Lys Gly Val Pro Leu Ile Lys Tyr Phe Ala Glu Ala Leu Gly Pro

15 20 25 30

ctg cag agc ttc cag gcc cgg cct gat gac ctg ctc atc agc acc tac 3867

Leu Gln Ser Phe Gln Ala Arg Pro Asp Asp Leu Leu Ile Ser Thr Tyr

35 40 45

ccc aag tcc ggt aggtgaggag ggccacccac cctctcccag gtggcagtcc 3919

Pro Lys Ser Gly

50

ccaccttggc cagcgaggtc atgctcacct cagcctgctc acctcccatc tccctccctc 3979

tccaggc acc acc tgg gtg agc cag att ctg gac atg atc tac cag ggc 4028

Thr Thr Trp Val Ser Gln Ile Leu Asp Met Ile Tyr Gln Gly

55 60

ggt gac ctg gaa aag tgt cac cga gct ccc atc ttc atg cgg gtg ccc 4076

Gly Asp Leu Glu Lys Cys His Arg Ala Pro Ile Phe Met Arg Val Pro

65 70 75 80

ttc ctt gag ttc aaa gtc cca ggg att ccc tca ggt gtgtgtgtcc 4122

Phe Leu Glu Phe Lys Val Pro Gly Ile Pro Ser Gly

85 90

tgggtgcaag gggagtggag gaagacaggg ctggggcttc agctcaccag accttccctg 4182

acccactgct caggg atg gag act ctg aaa aac aca cca gcc cca cga ctc 4233

Met Glu Thr Leu Lys Asn Thr Pro Ala Pro Arg Leu

95 100

ctg aag aca cac ctg ccc ctg gct ctg ctc ccc cag act ctg ttg gat 4281

Leu Lys Thr His Leu Pro Leu Ala Leu Leu Pro Gln Thr Leu Leu Asp

105 110 115 120

cag aag gtc aag gtgagactgg gcacagtggt tcacacccgc aatctcagta 4333

Gln Lys Val Lys

ctttgggagg ctgaggtggg aagatccctt gaagccagaa gttccagata agtctcttcc 4393

aaaaaaaaaa cttagctgtg catagtggtg tgtgcctgta ataccagtta ctcaggaggt 4453

tgaggtggga ggatcatctg agcctaggag tttaaggtta cagcgagcta tgatcacacc 4513

agtgcactcc aggctgggtg acagagaaac actgtctcaa aaaacgatga atagaaagag 4573

tgtcccacca gtgcggtggc tcacacctgt aattccagca cttgaagagg ctgaggcagg 4633

tggatcacct gagactagga gtttgagatc agcctggcca acatggcaaa accccatctc 4693

tactaaaaat acaaaaaaat tagccgggca tggtggcagg catctgtaat cccagctact 4753

tgggaggctg aagcaggaga attgcttgaa gctgggaggc agaggttgta gtcagccgag 4813

acctcaccat tgcaccgcag cctgggaaac aagagcaaaa ctctgtctca aaaaaaaaag 4873

aaaaaaataa aaaagcggca ggtggcaggg ggctgggcct gttgtggctc acgcctgtaa 4933

taccagcact ttcggaggtc gaggtgggca gatcacccaa ggttaggagt ttgagatcag 4993

tctggccaac atggagaaac cccgtctcta ctaaaaatac aaaaattagc caggcgttgg 5053

ggcaggcgcc agtaatccca gctactcggg aggctgagga aggagaatag cttgcacctg 5113

ggaggcggtg gttgcagtga gccgagattg tgccactgta ctccagcctg ggagacacaa 5173

cgagacattg tttcaaacaa aacaaataaa tattttaaaa ggtttgccac ctgggtggct 5233

caccgctgta atgccagcat tttgggaggc caagatgggt ggaccgcttg agctcaggag 5293

ttccagacca gcccaggaaa catggggaga ctccatctct ataaaagatg caaataatca 5353

gcagggcatg gtggcatagc gctatagtcc cagctactca aaagtctaag gttggaggat 5413

tgcttgagcc tgggaggtca acgttgcagt gagctattct cactccagtg cactccaacc 5473

tgggcaacag gaaaaaagaa agcccaaggt cttttttctc ttttctcttt tttttgagac 5533

ctagagtccc cccccccaaa aaaaaaaaaa ccacaacaaa aagaaaaaag caaaggtcca 5593

ggtgtggggc atgtgaatcc agggaaggag gccccggctc agcccagctt tggtcctgtt 5653

cttctgggag agtcgcctca cttcctccag acttgtctca tcttccacgg gggggactgt 5713

ctgccttttg ctctgatgac caaaaacatg agactcttcc gggtagacct aagaaaggta 5773

gagggtgggt cctcacagac ccacaaaatt tggtggtggt gggaacatgc ctggtggagc 5833

atgccttgct ccagatcggg gtgtgacgca ttgatgcaga ttatattact atagaatatg 5893

atggtctcag ggaccaggca ggactttggc ttttgagcag ggttcagatc ctgacttggc 5953

cctacctgtg ccgtgagatc tcaaacaagt cagcctctaa gcctcagctt cctcctttgc 6013

caaaccaaga gatgagctgg cctggggcag gctgtgtggt gatggtgctg gggttgagtc 6073

ttctgcccct gcag gtg gtc tat gtt gcc cgc aac gca aag gat gtg gcg 6123

Val Val Tyr Val Ala Arg Asn Ala Lys Asp Val Ala

125 130 135

gtt tcc tac tac cac ttc tac cac atg gcc aaa gtg tac cct cac cct 6171

Val Ser Tyr Tyr His Phe Tyr His Met Ala Lys Val Tyr Pro His Pro

140 145 150

ggg acc tgg gaa agc ttc ctg gag aag ttc atg gct gga gaa 6213

Gly Thr Trp Glu Ser Phe Leu Glu Lys Phe Met Ala Gly Glu

155 160 165

ggtgggcttg atgggaggaa ggaaggtgtg gagctaaggg gtggtggcta caacgcacag 6273

caaccctgtg tcggcacccc ctgcccgctt ctcca gtg tcc tat ggg tcc tgg 6326

Val Ser Tyr Gly Ser Trp

170

tac cag cac gtg caa gag tgg tgg gag ctg agc cgc acc cac cct gtt 6374

Tyr Gln His Val Gln Glu Trp Trp Glu Leu Ser Arg Thr His Pro Val

175 180 185

ctc tac ctc ttc tat gaa gac atg aag gag gtgagaccgc ctttgatgct 6424

Leu Tyr Leu Phe Tyr Glu Asp Met Lys Glu

190 195

tccctccacg tgacacctgg gggcaggcac ttcacaggga cctgccaagg ccacccagcc 6484

accctccctg ggcggcccct ccagcaggcc cggattcccc atcctgactc cctggcccag 6544

gccccactgc agccccatgt ggcagcaggc tgggcacagc tctcatctcc tgtgcctgag 6604

tcagctgcac gggtggccat ggatcagcta cttttttttt tgagacaaaa gtcttgctct 6664

gttgtccagg atggcatgca gtggtgtgat ctcagctcag tgtaaccccc cctcccaggt 6724

tcaagtgatt ctcctgcctc agcctcctga gtagctgaga ttacagatgc acactaccat 6784

gcctggctaa tttttgtgtt gtgccatgtt ggccaggttg gtctccatct cctgagctca 6844

ggtgatccgc ctgcctcagc ctcccaaagt cttgggaatt acacgcctga accacggccc 6904

cttgccacag atcagctatc tattccaatt gcttctccct gccaatggtt atgccaccca 6964

gggccacagg cacggaagaa gaccatccca gtccttaccc ataggagcca agcccagctc 7024

atgatgggat cacagggcag acagcaattc attttgcccc agggactggg gtcccagggg 7084

tcgaggagct ggctctatgg gttttgaagt ggaagtggcc agttcccctc tgaggttaga 7144

gaagtggacc ccttttattt tcctgaatca gcaatccaag cctccactga ggagccctct 7204

gctgctcag aac ccc aaa agg gag att caa aag atc ctg gag ttt gtg ggg 7255

Asn Pro Lys Arg Glu Ile Gln Lys Ile Leu Glu Phe Val Gly

200 205 210

cgc tcc ctg cca gag gag act gtg gac ctc atg gtt gag cac acg tcg 7303

Arg Ser Leu Pro Glu Glu Thr Val Asp Leu Met Val Glu His Thr Ser

215 220 225

ttc aag gag atg aag aag aac cct atg acc aac tac acc acc gtc cgc 7351

Phe Lys Glu Met Lys Lys Asn Pro Met Thr Asn Tyr Thr Thr Val Arg

230 235 240

cgg gag ttc atg gac cac agc atc tcc ccc ttc atg agg aaa 7393

Arg Glu Phe Met Asp His Ser Ile Ser Pro Phe Met Arg Lys

245 250 255

ggtaggtgcc ggccagcacg ggggtttgga gcaggtggga gcagcagctg gagcctcccc 7453

ataggcactc ggggcctccc ctgggatgag actccagctt tgctccctgc cttcctcccc 7513

ca ggc atg gct ggg gac tgg aag acc acc ttc acc gtg gcg cag aat 7560

Gly Met Ala Gly Asp Trp Lys Thr Thr Phe Thr Val Ala Gln Asn

260 265 270

gag cgc ttc gat gcg gac tat gcg gag aag atg gca ggc tgc agc ctc 7608

Glu Arg Phe Asp Ala Asp Tyr Ala Glu Lys Met Ala Gly Cys Ser Leu

275 280 285

agc ttc cgc tct gag ctg tga gaggggttcc tggagtcact gcagagggag 7659

Ser Phe Arg Ser Glu Leu *

290 295

tgtgcgaatc aagcctgacc aagaggctcc agaataaagt atgatttgtg ttcaatgcag 7719

agtctctatt ccaagccaag agaaaccctg agctgaaaga gtgatcgccc actggggcca 7779

aatacggcca cctccccgct ccagctcctc aacttgccct gtttggagag gggagagggt 7839

ctggagaagt aaaacccagg agacgagtag agggggaatg tgtttaatcc cagcacgtcc 7899

tctgctgtcc tgccctgtgt cgttggggga tggcgagtct gccaggcggc atcacttttt 7959

cttgggttcc ttacaagcca ccacgtatct ctgagccaca ttgaggggag gggaatagcc 8019

atctgcatag gaggtgtctt caaacaggac cgagtagtca tcctggggct gtggggcagg 8079

cagacaggag gggctgctca gagaccccca ggccaggaca ggcaccccct tcccccagcc 8139

tagaccacag gaggctctgg gccgtggact ctcagccact cctaacatcc ttcactctgg 8199

ggtcaagaag tcttggccca gtccctgctg ctacagagct cttttctcag tggctggaga 8259

cccaaggcag ggaataggca gggaggagta ggggtgctga ctcccttcct agtggggtca 8319

tagctggagg gtctgctgcc tttcaaggac tctttgttga gaggactgag ggcaacccag 8379

agggtggcag gcagggat 8397

<210> SEQ ID NO 38

<211> LENGTH: 50

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 38

Met Glu Leu Ile Gln Asp Ile Ser Arg Pro Pro Leu Glu Tyr Val Lys

1 5 10 15

Gly Val Pro Leu Ile Lys Tyr Phe Ala Glu Ala Leu Gly Pro Leu Gln

20 25 30

Ser Phe Gln Ala Arg Pro Asp Asp Leu Leu Ile Ser Thr Tyr Pro Lys

35 40 45

Ser Gly

50

<210> SEQ ID NO 39

<211> LENGTH: 42

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 39

Thr Thr Trp Val Ser Gln Ile Leu Asp Met Ile Tyr Gln Gly Gly Asp

1 5 10 15

Leu Glu Lys Cys His Arg Ala Pro Ile Phe Met Arg Val Pro Phe Leu

20 25 30

Glu Phe Lys Val Pro Gly Ile Pro Ser Gly

35 40

<210> SEQ ID NO 40

<211> LENGTH: 32

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 40

Met Glu Thr Leu Lys Asn Thr Pro Ala Pro Arg Leu Leu Lys Thr His

1 5 10 15

Leu Pro Leu Ala Leu Leu Pro Gln Thr Leu Leu Asp Gln Lys Val Lys

20 25 30

<210> SEQ ID NO 41

<211> LENGTH: 42

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 41

Val Val Tyr Val Ala Arg Asn Ala Lys Asp Val Ala Val Ser Tyr Tyr

1 5 10 15

His Phe Tyr His Met Ala Lys Val Tyr Pro His Pro Gly Thr Trp Glu

20 25 30

Ser Phe Leu Glu Lys Phe Met Ala Gly Glu

35 40

<210> SEQ ID NO 42

<211> LENGTH: 32

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 42

Val Ser Tyr Gly Ser Trp Tyr Gln His Val Gln Glu Trp Trp Glu Leu

1 5 10 15

Ser Arg Thr His Pro Val Leu Tyr Leu Phe Tyr Glu Asp Met Lys Glu

20 25 30

<210> SEQ ID NO 43

<211> LENGTH: 60

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 43

Asn Pro Lys Arg Glu Ile Gln Lys Ile Leu Glu Phe Val Gly Arg Ser

1 5 10 15

Leu Pro Glu Glu Thr Val Asp Leu Met Val Glu His Thr Ser Phe Lys

20 25 30

Glu Met Lys Lys Asn Pro Met Thr Asn Tyr Thr Thr Val Arg Arg Glu

35 40 45

Phe Met Asp His Ser Ile Ser Pro Phe Met Arg Lys

50 55 60

<210> SEQ ID NO 44

<211> LENGTH: 37

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 44

Gly Met Ala Gly Asp Trp Lys Thr Thr Phe Thr Val Ala Gln Asn Glu

1 5 10 15

Arg Phe Asp Ala Asp Tyr Ala Glu Lys Met Ala Gly Cys Ser Leu Ser

20 25 30

Phe Arg Ser Glu Leu

35

<210> SEQ ID NO 45

<211> LENGTH: 8447

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (4361)...(4507)

<221> NAME/KEY: CDS

<222> LOCATION: (4612)...(4737)

<221> NAME/KEY: CDS

<222> LOCATION: (4827)...(4925)

<221> NAME/KEY: CDS

<222> LOCATION: (6322)...(6447)

<221> NAME/KEY: CDS

<222> LOCATION: (6543)...(6638)

<221> NAME/KEY: CDS

<222> LOCATION: (7137)...(7316)

<221> NAME/KEY: CDS

<222> LOCATION: (7439)...(7553)

<400> SEQUENCE: 45

acctctgcct cctggttcca agcaatcctc cttcctcacc ctccagagta gctgggatta 60

cacgcgcctg ccaccgcgcc tggcctaatt tttgtatttt tagtagagat gggggtttcc 120

aaccatgttg gccaggctgg tctccaaact cctgacctca ggtgatcctg cccacctaag 180

cctcccaaaa tgctggtatt acaggcatga gccaccgtgc ccggcctaaa taattaataa 240

aataatggac gatgggtgcc ttctactgag ctcccggtaa ttgtgagtga gtagaggact 300

tgccctgggg acattcagtg acctgctggg tgttgctgag ctgtgaggaa gttcaggtct 360

ggctgcagtg gtgaggctgt gactcaatca atcactgctg atgctcccag gacctgcacc 420

agcttagtcc taggggcaag gattttaact gtccacctca gtttcttcat ttgtaagatg 480

caaataacag tcacccctgc ctcatgggat ggagctgtgt aatgcccgca acagtgcctg 540

ctgcatagag gggttgctgc cagctgcctc tccctccttg tctcttacct gcctgctgcc 600

tgggtcagga tgaagagggg cccttgtgtt gcccccaccc tggctgcctg ctaagggccc 660

atgtgatctg cctggcagag gagtttcttc aggaagaacc agggcagctt ctgcccctag 720

agggccaatg cccttggtga gtgcagtccc ctggccccag cctggtccac ctctgggaag 780

agggtgccca gttgtgcaat ccaggcccag gcagctgagc cctcatctca gcatgcaggg 840

cggatactgg agggggcttg tggcatctga ctctgtatct cctacctgcc cctctccttg 900

gtagctgtga gaagtcactg ctttggggag acctgatctg gctgtgccag atggacactg 960

agaaagaagt agaagactca gaattagaag aggtgagtgg gctttggtgg cgggctccct 1020

accccactcc ctgccctggg ctgcctgtga ccacactgct tgcctctgca ggcacactgg 1080

acagacctgc tggagacctg atcctcagtg tccttacccc ctcctacctc ttttctgtgc 1140

cacctgctgt gggtccagca ggtttttact tgagtacaat aaaaagtctg agtcaagggt 1200

gccttatggt ggatgctgag gggaggggcg gagctagtag cccaaggtcc tgccagtcac 1260

ggggcttcct caggggcaca gaggaggcag gaggggcccc tggccctagc acgtgaacag 1320

cttctactct gcctggaaac cccatgcctc agctttcccc tacttgcctc tgagctcatg 1380

caattcttgg aagcctggga gacttacctt gaaattgaat gcaaatagga caaagaccaa 1440

ggaggatggg gggatgccct ccttccacgg ggccctgtgg cttccaagtc ttaatctcct 1500

ctagtctctt gtctacggag cctccttcaa acccagggaa agaaaagcac ctgccagggt 1560

tgtttttctt ctaggatctt ctattgatgc tctgtgaggt cccccaggag ccatgaagct 1620

agggctggct cctagggcaa tgggactaca gtgtccttgt cctttcttat tctttctgtt 1680

ctttctttct ttcttttttt tttttttttt tttttttgag acagagtctc actctgttgc 1740

ccaggctgga gtgcagtggt gtgatcttgg ctcactgaaa cctccgcctc ctgggttcaa 1800

gtgattctct tgcctcagcc tcctgagtag ctaggattac aggtgcccgc catcatgccc 1860

agctaatttt tgtattttta gtagagacag ggtttcacca tgttggccag cttggtctcg 1920

aactcctgac ctcaggtgat cctgctgcat cgacctccca aagtactggg attacaggcg 1980

tgagccacca cgctcagcct ctttcttgtt ctatatgtcc atgctctgct ccacttctgc 2040

cccttcactc tgccccacac atcactccag actggccttg tggtcagagc ctggaatgcc 2100

tgggctgctg ggggcctgtg gactgcactg ggccagaacc cctgccgcct tcaagactgg 2160

cctgtagcca gcaggtaggt gacttttccc aggccggcct atcccacctt tcccctccac 2220

tcactcacct cccttgcctg ggtcaattag agaaagcttg tcggccaggc atggtggctc 2280

atgcctgtaa tctcagcact ttgggaggcc gaggcgggcg gatcatctga gctcaggagt 2340

ttgagaccag cctggccaac atggcaaaac cccgtctcta ctaaaaatac aaaaattaac 2400

cggatgtggt ggtgtgcacc tgtaatccca gctactcggg aggctgaggc agaagaatcg 2460

cttgaaccca ggagggggag gttacagtga gcggagatcg tgctactgca ttgcagcctg 2520

ggcgagagag cgagtctcca tctcacataa aaaaaagaaa aagaaagaaa gcaagcttgt 2580

ctgttggcct gccctgcagg gtggagttca gagggaaggt caggagccta gtgacagctc 2640

aaaaaaaaaa aaacccaaat accaatgttg gccccttttg cctttcattc atgtgttttc 2700

tatacactaa actcacatat tgggtttgca gatcactcca agcttggctg gagctgtggt 2760

ggtaaggagg gtaatagaga agcttcccca ccctcaaccc caccccttcc ttcctggagt 2820

tcccagccct gactttagat ccctcccaca ctggaccttc aaaaccctca gggcagagag 2880

cagccctaca ctccctacac cacacccata ctcagcccct gcaggcaagg agagaacagg 2940

tcaggttccc gagagctcag gtgagtgaca cgttggaatg gcccagggca ccttcaccct 3000

gctcagcttg tggctccaac attctagaag ccgaggcctc tgccatccct gccctttccc 3060

atggatattc catttcaatt agacaaccca gcctggccgg aatccccctg cgttccttct 3120

tttcctttgt gtatttttga gacagggtgt tgctccgtca cccaggctgg agtgtagtgg 3180

gatcctggcc cactgcagcc tcaaattcct aggctgaggc aatcctgccg cctcagcctc 3240

ctgagtagct ggggttacaa gagcaagcca ccacacccag ctaattttga aaaatatttt 3300

ttgtagagga gaggtcttgc tttgttgtcc aggttggtct caaactccag ggctcaaggg 3360

atcctttccc gttggcctcc caaggctctg ggattacagg cgggagtcac cctgcctggg 3420

cccctccttt tgatgagtca tcagttttca ttcccgcacg aggctctagc ccctggtacc 3480

agcttagttg ctcaatgggc tgtgtttgtt ctggagccca gatggactgt ggccaggcaa 3540

gtggatcaca gacctggccg gcctgggagg tttccacatg tgaggggcat gaggggggct 3600

caaggagggg agcatcgggg agaggagcgc actgggtgga ggctgggggt cccagcagga 3660

aatggtgaga caaagggcgc tggctggcag ggagacagca caggcaggcc ctagagcttc 3720

ctcagcacag ctggactctc ctggagacct tcacacaccc tgatatctgg gccccgcgct 3780

acgagggtgc tttcactggt ctgcactatg ccccaggccc tgggattttg aacagctctg 3840

caggtgactg aaaggtgcgg ccaggctggg gaacgacctg gtttcagccc cagccccgcc 3900

actgactgac tttgtgagtg cgggcaagtc actcagcctc cctaggcctc agtgacttcc 3960

ctgaaagcaa aaactctgca aaggggcagc tgggtgctgg ctcacacctg taatcccagc 4020

actttgggag gctgaggtag acaaatcact tgaggccagg agttctagac cagcctggcc 4080

aacatggtga aaccccatct ctactaaaga aaaaaaaaaa ttagctgagc atggttgtac 4140

atgcttgtaa tcccagctac ttgggatgcc gaggcgggag gattgcttga acccaagagg 4200

tggagtttgc agtgagctga gattgtgcca cactgcactc cagcttgggt gagagtgaga 4260

ctccatctca aaaaaaaaaa aaaaaagaga gaatcccact ttcttgctgt tgtgatggtg 4320

gtaagggaac gggcctggct ctggcccctg atgcaggaac atg gag ctg atc cag 4375

Met Glu Leu Ile Gln

1 5

gac acc tcc cgc ccg cca ctg gag tac gtg aag ggg gtc ccg ctc atc 4423

Asp Thr Ser Arg Pro Pro Leu Glu Tyr Val Lys Gly Val Pro Leu Ile

10 15 20

aag tac ttt gca gag gca ctg ggg ccc ctg cag agc ttc caa gcc cga 4471

Lys Tyr Phe Ala Glu Ala Leu Gly Pro Leu Gln Ser Phe Gln Ala Arg

25 30 35

cct gat gac ctg ctc atc aac acc tac ccc aag tct ggtaagtgag 4517

Pro Asp Asp Leu Leu Ile Asn Thr Tyr Pro Lys Ser

40 45

gagggccacc caccctctcc caggcggcag tccccacctt ggtcagcaag gtcgtgccct 4577

cagcctgctc acctcctatc tccctccctc tcca ggc acc acc tgg gtg agc cag 4632

Gly Thr Thr Trp Val Ser Gln

50 55

ata ctg gac atg atc tac cag ggc ggc gac cta gag aag tgt aac cgg 4680

Ile Leu Asp Met Ile Tyr Gln Gly Gly Asp Leu Glu Lys Cys Asn Arg

60 65 70

gct ccc atc tac gta cgg gtg ccc ttc ctt gag gtc aat gat cca ggg 4728

Ala Pro Ile Tyr Val Arg Val Pro Phe Leu Glu Val Asn Asp Pro Gly

75 80 85

gaa ccc tca ggtgcatggc tgggtcctgg gggtaaggga agtggaggaa 4777

Glu Pro Ser

90

gacagggctg gggcttcagc tcaccagacc ttccctgacc cactactca ggg ctg gag 4835

Gly Leu Glu

act ctg aaa gac aca ccg ccc cca cgg ctc atc aag tca cac ctg ccc 4883

Thr Leu Lys Asp Thr Pro Pro Pro Arg Leu Ile Lys Ser His Leu Pro

95 100 105 110

ctg gct ctg ctc cct cag act ctg ttg gat cag aag gtc aag 4925

Leu Ala Leu Leu Pro Gln Thr Leu Leu Asp Gln Lys Val Lys

115 120

gtgaggccgg cctcaatggt tcacacctgt catcccagtt tgagactgag gagggaggat 4985

cccttgaagg cgagagatgg agaccagcct gggcaacatt gctgtagaga tgacatccca 5045

tctctacaaa aataaaatta acaacctggt atggtggcat agactgttcc cagttactta 5105

ggaggctcag cggggaggac tgtttatgca aataggaagc tgcaatgagc cctgatgatc 5165

ctgctgctgc actccagcct gggcaacaca gcaaaaccat ctctacgaaa aaaaaagttc 5225

ccactgactg gcaaggaaag ccaggaaggg gggctcaggt gccctctcag ccatgtacct 5285

gttcttctgg aagggcctcc tcgcttctgc caggctcatc acatcttttt tttttttgag 5345

acagagtctt gctctgtcac cctggctgga gtgcagtggc atgatctcag ctcactgcaa 5405

cctccgcctc cccagttcaa gtgattctcc tgcctcagcc tcctgagtag ctgggattac 5465

aggcgtgtgc taccacaccc ggctaatttt tgtattcttt ttagtagaga cggggtttca 5525

ccatgttggt caagtggatc tcaaactctt gaccttgtga tcctcctgcc tcgacctcac 5585

aaagtgctgg aattacaggc gtgagccacc gcgcctggcc cttttttttt ttgagacagt 5645

ttcactcttg ttgccgaggc tagagcgcaa tcgtgtgatc tcggttcact gcaaccaccg 5705

cctcctgggt tcaagcaatt ctcctgcttc agcctcccaa ggagctggga ttacaggtac 5765

ctgccaccac gcccggctaa ttttgtattt ttagtagaga tggggtttca ccatgttggt 5825

caggctggtc ttgaactcct gacctcaggt gatctggcac cttggcctcc caaagtgccg 5885

ggattagagg catgagccac cacgcccagc cttcatcaca tcttgagaga ggacactgtc 5945

tgcctcttgc tctgatgagg gtctgatgca aaggatagtg agtctctaca gtgcacactt 6005

aagaaaggca gcatgtgggt gctcacaggt caggcggagg agggggagct ggtggggacc 6065

aggcatgcct tgctccagat caggatatga tggcattggt gcagattata ttagtataga 6125

atatggtctc aggaaccagg caggactttg gcttccgagc agggttcaga tcccagcttg 6185

gccctacctg tgcagtgaga tctcaagcaa gtcagcctct aagcctcagg ttcctccttt 6245

gccagttcaa cagatgagct ggcctggggt gggctgtgtg gtgatggtgc tggggctggg 6305

tcctctgccc ctgcag gtg gtc tat gtt gcc cga aac cca aag gac gtg gcg 6357

Val Val Tyr Val Ala Arg Asn Pro Lys Asp Val Ala

125 130 135

gtc tcc tac tac cat ttc cac cgt atg gaa aag gcg cac cct gag cct 6405

Val Ser Tyr Tyr His Phe His Arg Met Glu Lys Ala His Pro Glu Pro

140 145 150

ggg acc tgg gac agc ttc ctg gaa aag ttc atg gct gga gaa 6447

Gly Thr Trp Asp Ser Phe Leu Glu Lys Phe Met Ala Gly Glu

155 160 165

ggtgggcttg actggaggaa ggagggtgtg aagccgaggg gtggtggcta taacgtacag 6507

caaccctgtg tcggtgcccc ctgcccgctt ctcta gtg tcc tac ggg tcc tgg 6560

Val Ser Tyr Gly Ser Trp

170

tac cag cac gtg cag gag tgg tgg gag ctg agc cgc acc cac cct gtt 6608

Tyr Gln His Val Gln Glu Trp Trp Glu Leu Ser Arg Thr His Pro Val

175 180 185

ctc tac ctc ttc tat gaa gac atg aag gag gtgagaccga ctgtgatgct 6658

Leu Tyr Leu Phe Tyr Glu Asp Met Lys Glu

190 195

tccccccatg tgacacctgg gggcaggcac ctcacaggga cccaccaagg ccacccagcc 6718

ccgtccctgg gcggctccca cagcaagccc ggattcccca tcctacctcc ctggcccagg 6778

cccccccact gcagccccac ctggcagcag gctcggcaca gctttcatct tctgcacctg 6838

agtcagctgc atgggtggcc acggatcaga tacttagtcc tattgcttat cctcaccaaa 6898

gggtgtgcca cccagggcca cagtcatgga agaagaccat cccggtcctc acccataggc 6958

gccaagccct gttcatgatg ggatcacagg gcagagatca attcatttta ctccagagac 7018

tagggcccca ggggttgagg ctctttgggg tttctagggg aagtggccag atcccctctg 7078

aggttagaga gggggacccg ttttgttttg ctccactgag gagccctctg ctgctcag 7136

aac ccc aaa agg gag att caa aag atc ctg gag ttt gtg ggg cgc tcc 7184

Asn Pro Lys Arg Glu Ile Gln Lys Ile Leu Glu Phe Val Gly Arg Ser

200 205 210

ctg cca gag gag acc atg gac ttc atg gtt cag cac acg tcg ttc aag 7232

Leu Pro Glu Glu Thr Met Asp Phe Met Val Gln His Thr Ser Phe Lys

215 220 225 230

gag atg aag aag aac cct atg acc aac tac acc acc gtc ccc cag gag 7280

Glu Met Lys Lys Asn Pro Met Thr Asn Tyr Thr Thr Val Pro Gln Glu

235 240 245

ctc atg gac cac agc atc tcc ccc ttc atg agg aaa ggtgggtgct 7326

Leu Met Asp His Ser Ile Ser Pro Phe Met Arg Lys

250 255

ggccagcacg ggggtttggg gcgggtggga gcagcagctg cagcctcccc ataggcactt 7386

ggggcctccc ctgggatgag actccagctt tgctccctgc cttcctcccc ca ggc atg 7444

Gly Met

260

gct ggg gac tgg aag acc acc ttc acc gtg gcg cag aat gag cgc ttc 7492

Ala Gly Asp Trp Lys Thr Thr Phe Thr Val Ala Gln Asn Glu Arg Phe

265 270 275

gat gcg gac tat gcg gag aag atg gca ggc tgc agc ctc agc ttc cgc 7540

Asp Ala Asp Tyr Ala Glu Lys Met Ala Gly Cys Ser Leu Ser Phe Arg

280 285 290

tct gag ctg tga g aggggctcct ggagtcactg cagagggagt gtgcgaatct 7593

Ser Glu Leu *

295

accctgacca atgggctcaa gaataaagta tgatttttga gtcaggcaca gtggctcatg 7653

tctgcaatcc cagcgatttg ggaggttgag ctggtaggat cacaataggc cacgaatttg 7713

agaccagcct ggtaaaatag tgagacctca tctctacaaa gatgtaaaaa aattagccac 7773

atgtgctggc acttacctgt agtcccagct acttgggaag cagaggctgg aggatcattt 7833

cagcccagga ggttgtggat acagtgagtt atgacatgcc cattcactac agcctggatg 7893

acaagcaaga ccctccctcc aaagaaaata aagctcaatt aaaataaaat atgatttgtg 7953

ttcatgtaga gcctgtattg gaaaggaaga gaaactctga gctgaaagag tgaatgcccg 8013

gtggggccac atatggtcac ctctccccca gccttcagct ccccaggtca ccatatctgg 8073

ggaggggaga agggtttgga gaagtaaaac ccaggagatg tgtggagggg ggatgtctgt 8133

ttaatcccag cacatcctct gctgtcctgc cccaagatgg tggaggacgt cgagtccgcc 8193

gggcagcgtc actttttctt gggctcctta gaagctacca ggtacctctg ggccacactg 8253

agatgagggg agtagccgcc tgcataggag gtgtcttcaa acaggatagt atagtccctc 8313

ctgggggttg tgggggtagg tggccaagga agggtagagg agcaagcccc cggggctggt 8373

tgtcaactca ctttgttggc tggaattggt tgtaacttga ccacctcggg caggatccca 8433

ctgctcatcc ccaa 8447

<210> SEQ ID NO 46

<211> LENGTH: 49

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 46

Met Glu Leu Ile Gln Asp Thr Ser Arg Pro Pro Leu Glu Tyr Val Lys

1 5 10 15

Gly Val Pro Leu Ile Lys Tyr Phe Ala Glu Ala Leu Gly Pro Leu Gln

20 25 30

Ser Phe Gln Ala Arg Pro Asp Asp Leu Leu Ile Asn Thr Tyr Pro Lys

35 40 45

Ser

<210> SEQ ID NO 47

<211> LENGTH: 42

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 47

Gly Thr Thr Trp Val Ser Gln Ile Leu Asp Met Ile Tyr Gln Gly Gly

1 5 10 15

Asp Leu Glu Lys Cys Asn Arg Ala Pro Ile Tyr Val Arg Val Pro Phe

20 25 30

Leu Glu Val Asn Asp Pro Gly Glu Pro Ser

35 40

<210> SEQ ID NO 48

<211> LENGTH: 33

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 48

Gly Leu Glu Thr Leu Lys Asp Thr Pro Pro Pro Arg Leu Ile Lys Ser

1 5 10 15

His Leu Pro Leu Ala Leu Leu Pro Gln Thr Leu Leu Asp Gln Lys Val

20 25 30

Lys

<210> SEQ ID NO 49

<211> LENGTH: 42

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 49

Val Val Tyr Val Ala Arg Asn Pro Lys Asp Val Ala Val Ser Tyr Tyr

1 5 10 15

His Phe His Arg Met Glu Lys Ala His Pro Glu Pro Gly Thr Trp Asp

20 25 30

Ser Phe Leu Glu Lys Phe Met Ala Gly Glu

35 40

<210> SEQ ID NO 50

<211> LENGTH: 32

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 50

Val Ser Tyr Gly Ser Trp Tyr Gln His Val Gln Glu Trp Trp Glu Leu

1 5 10 15

Ser Arg Thr His Pro Val Leu Tyr Leu Phe Tyr Glu Asp Met Lys Glu

20 25 30

<210> SEQ ID NO 51

<211> LENGTH: 60

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 51

Asn Pro Lys Arg Glu Ile Gln Lys Ile Leu Glu Phe Val Gly Arg Ser

1 5 10 15

Leu Pro Glu Glu Thr Met Asp Phe Met Val Gln His Thr Ser Phe Lys

20 25 30

Glu Met Lys Lys Asn Pro Met Thr Asn Tyr Thr Thr Val Pro Gln Glu

35 40 45

Leu Met Asp His Ser Ile Ser Pro Phe Met Arg Lys

50 55 60

<210> SEQ ID NO 52

<211> LENGTH: 37

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 52

Gly Met Ala Gly Asp Trp Lys Thr Thr Phe Thr Val Ala Gln Asn Glu

1 5 10 15

Arg Phe Asp Ala Asp Tyr Ala Glu Lys Met Ala Gly Cys Ser Leu Ser

20 25 30

Phe Arg Ser Glu Leu

35

Claims

What is claimed is:

1. An isolated nucleic acid molecule comprising a SULT1A3 nucleic acid sequence, wherein said SULT1A3 nucleic acid sequence comprises a nucleotide sequence variant and nucleotides flanking said sequence variant.

2. The isolated nucleic acid molecule of claim 1, wherein said SULT1A3 nucleic acid sequence encodes a sulfotransferase polypeptide, said sulfotransferase polypeptide comprising an amino acid sequence variant.

3. The isolated nucleic acid molecule of claim 1, wherein said nucleotide sequence variant is within an intron sequence.

4. The isolated nucleic acid molecule of claim 1, wherein said nucleotide sequence variant comprises a guanine at nucleotide 105 of the coding sequence of said sulfotransferase nucleic acid sequence.

5. The isolated nucleic acid molecule of claim 1, wherein said nucleotide sequence variant comprises a nucleotide insertion within intron 3.

6. The isolated nucleic acid molecule of claim 5, wherein said nucleotide insertion comprises the nucleotide sequence of 5′-CAGT-3′.

7. The isolated nucleic acid molecule of claim 1, wherein said nucleotide sequence variant comprises an adenine at nucleotide 69 of intron 4.

8. The isolated nucleic acid molecule of claim 1, wherein said nucleotide sequence variant comprises an adenine at nucleotide 69 of intron 6.

9. The isolated nucleic acid molecule of claim 1, wherein said nucleotide sequence variant comprises a thymine at nucleotide 113 of intron 7.

10. An isolated nucleic acid molecule comprising a SULT1A1 nucleic acid sequence, wherein said SULT1A1 nucleic acid sequence comprises a nucleotide sequence variant and nucleotides flanking said sequence variant, and wherein said nucleotide sequence variant is selected from the group consisting of a cytosine at nucleotide 138 of intron 1A, a thymine at nucleotide 34 of intron 5, an adenine at nucleotide 57 of the coding sequence, an adenine at nucleotide 110 of the coding sequence, and an adenine at nucleotide 645 of the coding sequence.

11. The isolated nucleic acid molecule of claim 10, wherein said SULT1A1 nucleic acid sequence encodes a sulfotransferase polypeptide having a glutamine at amino acid residue 37.

12. An isolated nucleic acid molecule comprising a SULT1A2 nucleic acid sequence, wherein said SULT1A2 nucleic acid sequence comprises a nucleotide sequence variant and nucleotides flanking said sequence variant, and wherein said nucleotide sequence variant is selected from the group consisting of a thymine at nucleotide 550 of the coding sequence, a thymine at nucleotide 78 of intron 5, and a thymine at nucleotide 9 of intron 7.

13. The isolated nucleic acid molecule of claim 12, wherein said SULT1A2 nucleic acid sequence encodes a sulfotransferase polypeptide having a cysteine at amino acid residue 184.

14. A method for determining a risk estimate of a hormone dependent disease in a subject, said method comprising detecting the presence or absence of a sulfotransferase nucleotide sequence variant in said patient, and determining said risk estimate based, at least in part, on presence or absence of said variant in said subject.

15. The method of claim 14, wherein said hormone dependent disease is breast cancer.

16. The method of claim 14, wherein said hormone dependent disease is prostate cancer.

17. The method of claim 14, wherein said hormone dependent disease is ovarian cancer.

18. A method for determining sulfonator status in a subject, said method comprising detecting the presence or absence of a sulfotransferase allozyme in said subject, and determining said sulfonator status based, at least in part, on presence or absence of said sulfotransferase allozyme.

19. An antibody having specific binding affinity for a sulfotransferase polypeptide, said polypeptide comprising an amino acid sequence variant.

20. A nucleic acid construct, said construct comprising a SULT1A3 nucleic acid sequence operably linked to a regulatory nucleic acid sequence, said SULT1A3 nucleic acid sequence comprising a nucleotide sequence variant and nucleotides flanking said variant.

21. An isolated nucleic acid molecule comprising a sulfotransferase nucleic acid sequence, wherein said sequence encodes a sulfotransferase allozyme selected from the group consisting of SULT1A1*4, SULT1A2*4, SULT1A2*5, and SULT1A2*6.

22. An isolated nucleic acid molecule comprising a sulfotransferase nucleic acid sequence, wherein said sulfotransferase nucleic acid sequence is a sulfotransferase allele selected from the group consisting of SULT1A1, SULT1A2, SULT1A1*3A, SULT1A1*3B, and SULT1A1*4.

23. The isolated nucleic acid molecule of claim 22, wherein said SULT1A1 allele is selected from the group consisting of SULT1A1*1A, SULT1A1*1B, SULT1A1*1C, SULT1A1*1D, SULT1A1*1E, SULT1A1*1F, SULT1A1*1G, SULT1A1*1H, SULT1A1*1I, SULT1A1*1J and SULT1A1*1K.

24. The isolated nucleic acid molecule of claim 22, wherein said SULT1A2 allele is selected from the group consisting of SULT1A2*1A, SULT1A2*1B, SULT1A2*1C, SULT1A2*D, SULT1A2*2A, SULT1A2*2B, SULT1A2*2C, SULT1A2*3A, SULT1A2*3B, SULT1A2*3C, SULT1A2*4, SULT1A2*5 and SULT1A2*6.

25. An article of manufacture comprising a substrate and an array of different sulfotransferase nucleic acid molecules immobilized on said substrate, wherein each of said different sulfotransferase nucleic acid molecules comprises a different sulfotransferase nucleotide sequence variant and nucleotides flanking said sequence variant.

26. The article of manufacture of claim 25, wherein said array comprises at least two nucleotide sequence variants of SULT1A1.

27. The article of manufacture of claim 26, wherein said array comprises the following SULT1A1 variants: a cytosine at nucleotide 138 of intron 1A, a thymine at nucleotide 34 of intron 5, an adenine at nucleotide 35 of intron 5, a guanine at nucleotide 11 of intron 6, a cytosine at nucleotide 14 of intron 6, a thymine at nucleotide 17 of intron 6, a thymine at nucleotide 35 of intron 6, an adenine at nucleotide 45 of intron 6, a guanine at nucleotide 64 of intron 6, a cytosine at nucleotide 488 of intron 6, an adenine at nucleotide 509 of intron 6, a thymine at nucleotide 16 of intron 7, a cytosine at nucleotide 69 of intron 7, a guanine at nucleotide 120 of intron 7, an adenine at nucleotide 57 of the coding sequence, an adenine at nucleotide 110 of the coding sequence, a cytosine at nucleotide 153 of the coding sequence, a guanine at nucleotide 162 of the coding sequence, a cytosine at nucleotide 600 of the coding sequence, an adenine at nucleotide 638 of the coding sequence, an adenine at nucleotide 645 of the coding sequence, a guanine at nucleotide 667 of the coding sequence, a guanine at nucleotide 902 of the 3′ untranslated region, and a thymine at nucleotide 973 of the 3′ untranslated region.

28. The article of manufacture of claim 25, wherein said array comprises at least two nucleotide sequence variants of SULT1A2.

29. The article of manufacture of claim 28, wherein said array comprises the following SULT1A2 variants: a cytosine at nucleotide 20 of the coding sequence, a cytosine at nucleotide 24 of the coding sequence, a thymine at nucleotide 56 of the coding sequence, a thymine at nucleotide 550 of the coding sequence, a cytosine at nucleotide 704 of the coding sequence, a cytosine at nucleotide 895 of the 3′ untranslated region, a guanine at nucleotide 902 of the 3′ untranslated region, a cytosine at nucleotide 34 of intron 2, a thymine at nucleotide 78 of intron 5, and a thymine at nucleotide 9 of intron 7.

30. The article of manufacture of claim 25, wherein said array comprises at least two nucleotide sequence variants of SULT1A3.

31. The article of manufacture of claim 28, wherein said array comprises the following SULT1A3 variants: a guanine at nucleotide 105 of the coding sequence, an insertion of the nucleotide sequence 5′-CAGT-3′ within intron 3, an adenine at nucleotide 69 of intron 4, an adenine at nucleotide 69 of intron 6, and a thymine at nucleotide 113 of intron 7.